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Abstract 
The ubiquitin signaling pathway (USP) consists of hundreds of enzymes which are tightly 
regulated for proper maintenance of intracellular protein level homeostasis. The main goals of 
this thesis were to characterize the interaction of two proteins involved in the USP, the E3 
ubiquitin ligase called parkin, and the Deubiquitinating (DUB) enzyme, ataxin-3. The effect of 
disease-state substitutions in the parkin ubiquitin-like domain (UbLD) on the interaction with 
ataxin-3 was investigated through NMR 1H-15N HSQC titration experiments and affinity binding 
assays. The three UIM regions in ataxin-3 bind the hydrophobic patch of parkin UbLD (KD = 230 
µM) and are proposed to use a multivalent binding mechanism. The disease-state UbLD proteins 
(UbLDV15M, UbLDR33Q, UbLDK48A) retain their interaction with ataxin-3. Other DUB enzymes 
and E3 ligases have been reported to have regulatory interplay, which has triggered interest in 
studying protein pairings such as ataxin-3 and parkin. 
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Chapter 1 
INTRODUCTION 
1.1 The ubiquitin signaling pathway  
Protein degradation is a tightly orchestrated process that is required to maintain 
protein level homeostasis, which is essential for biological pathways such as cellular 
division, DNA repair, and proteasomal degradation. The ubiquitination signaling pathway 
(USP) is most famously known for its role in eukaryotic protein degradation by sending 
specific proteins to the proteasomal degradation machinery at the right time. The 
ubiquitin (Ub) molecule is 8.6 kDa, globular in shape, very robust and highly conserved 
in all eukaryotes. A cascade of three enzymes, the ubiquitin-activating (E1), ubiquitin-
conjugating (E2), and ubiquitin-ligase (E3) enzymes are utilized for attaching a mono-
ubiquitin species or building a chain of ubiquitin moieties on a substrate (Figure 1.1). 
These enzymes were originally named in the order that they were eluted from an anion-
exchange column (1). The covalent attachment of Ub moieties to substrates is an ATP 
driven process and is done so in a specific manner which is facilitated by the multiple 
combinations of E1, E2 and E3. Of the three classes of proteins involved in 
ubiquitination, the E3 ubiquitin ligase proteins has been an especially attractive target for 
macromolecular research due to the discovery of more than 1000 different homologues, 
suggesting that the E3 protein is heavily contributing to the substrate specificity in the 
pathway (2). To date there are ~1000 human E3 enzymes identified, ~40 E2 enzymes, 
and 2 E1 enzymes identified (3). An addition to the complexity of Ub attachment is the 
type of linkage that can be made between adjacent Ub moieties in a poly-Ub chain. There 
are 7 linkage possibilities, due to the presence of seven lysine residues within the Ub 
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Figure 1.1 Schematic of the conjugation and recycling process in the ubiquitin signaling 
  
Figure 1.1 Schematic of the ubiquitin conjugation and recycling process in the 
ubiquitin signaling pathway. Ubiquitin (Ub) is a signaling molecule that is 
conjugated onto a target protein to signal for essential cellular processes such as a 
degradation signal, DNA repair, or endocytosis. The Ub is activated by the E1 
activating enzyme, which requires an ATP molecule for the formation of a high 
energy thiolester bond to form between E1-Ub. The E1 then transfers the Ub 
moiety to the E2 enzyme, forming the Ub-E2 complex. Then the E3 acts as a 
scaffold protein to direct the Ub directly from the E2 to the target substrate, on the 
condition that it is a RING-type E3 enzyme. The target protein can have either a 
monoubiquitin attached or, after successive rounds of the E1-E2-E3 cascade, the 
target protein can have a poly-Ub chain attached. This process is reversible by 
deubiquitinating (DUB) enzymes, which act to detach Ub moieties to recycle Ub 
molecules, edit Ub conjugation errors, or for Ub processing. 
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molecule, and the arrangement of the linkages provide variety in the orientation of the Ub 
chain in three dimensional space. The type of linkage that is created in a poly-Ub chain, 
is a unique signal, which determines the fate of the substrate that its attached to. The most 
studied linkage pattern is the Lys48 Ub linkage which is known to signal for proteasomal 
degradation (4). 
The multistep enzymatic reaction for attachment of a ubiquitin moiety to a 
substrate protein is also a reversible process. The group of enzymes that perform the 
reverse reaction are known as ubiquitin specific proteases or deubiquitinating (DUB) 
enzymes and in mammals there are 5 gene families of DUB enzymes: Ubiquitin C-
terminal Hydrolases (UCHs), Ubiquitin-specific Peptidases (UBPs), Ovarian Tumor 
domain proteins (OTU), Josephin proteins and the Jab1/MPN domain-associated 
Metalloisopeptidase (JAMM) domain proteins (5). Most of these DUB enzymes are 
cysteine proteases, which utilize three residues, called the catalytic triad, including the 
cysteine that has the essential thiol group for catalyzing the Ub hydrolysis (6) (Figure 
1.2). 
Currently, there is interest in understanding how E3 enzymes are able to recognize 
specific substrates, and due to the large numbers of E2 and E3 enzymes available, many 
E2/E3 combinations are possible. Interestingly, certain E3 ligases have been found to 
interact with specific DUB enzymes, which seems counter-intuitive in the context of 
energetics used for Ub chain building. However, when considering the possibility of 
errors in attaching Ub to the correct substrate and using the correct linkage, and constant   
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Figure 1.2 Ribbon representation of DUB enzymes, each enzyme belongs to one 
of the five families of DUB enzymes. The DUB enzyme belonging to the USP, UCH, 
OTU, and MJD domains all have a conserved catalytic triad consisting of a Cys, His 
and Asp residue. The catalytic triad is depicted in blue with the side chains portrayed. 
The JAMM domain is a metalloisopeptidase and does not utilize a catalytic triad. The 
name of the protein is indicated beside the catalytic domain ribbon representation. The 
ribbon depictions were created in PyMOL and the PDB for USP7 (1NBF), UCH-L3 
(1XD3), OTU2 (1TFF), ataxin-3 (1YXB), and JAMM (1R5X). 
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reversibility requirements for cellular environment changes, there seems to be a need for 
DUB enzymes to rapidly edit these problems to adapt to a constantly changing cellular 
environment (7, 8). When the maintenance of protein homeostasis is abnormal in the cell, 
disease prone events like protein misfolding and aggregation can occur. Enzymes 
involved in the USP have been linked to neurodegenerative diseases, such as Parkinson’s 
disease and Spinocerebellar ataxias (7).  
 
1.2 E3 ubiquitin ligase  
E3 Ub-ligases fall under two major groups, the HECT (Homologous to E6-AP C-
terminal domain) or RING (Really Interesting New Gene) group (8). Apart from their 
unique structural features, they are also set apart from one another in their function as an 
E3 ligase protein. The HECT type E3 ligases form a thioester intermediate with Ub and 
further mediates the transfer to the substrate protein. RING type E3 enzymes are different 
and often described as more of a scaffold protein, which functions to interact with an E2-
Ub conjugate and substrate to mediate the transfer of the Ub moiety directly from the E2 
(8).   
1.3 Parkin 
1.3.1 PARK2 gene and domain architecture, expression of parkin, subcellular 
localization and function 
  PARK2 is the gene encoding the parkin protein and its location in the human 
genome, based on positional cloning, is on the long arm of chromosome 6 (6q25.2-27) 
(9). PARK2 is a large gene spanning 1.5 megabases containing 12 exons and is expressed 
   6
  
in many tissue types such as brain, skeletal muscle, and heart (10, 11). Interestingly, it is 
expressed in many areas of the brain including the substantia nigra (10).  
  Parkin is a RING-type E3 ligase composed of 465 residues and has a molecular 
weight of 52 kDa. Parkin consists of multiple domains; listed from the N-terminus to C-
terminus, UbLD (Ubiquitin-Like Domain), UPD (Unique-Parkin Domain), RING0, 
RING1, IBR (In-Between-RING), followed by RING2 (12) (Figure 1.3). The RING 
domains and IBR domain contain two Zn2+ ions each that are coordinated by cysteine and 
histidine residues. Without the Zn2+ ions, two of the protein domains (IBR, RING2) 
become completely unfolded (12). 
 The discoveries that identified parkin as a USP protein came from evidence that it 
has E3 ligase activity and could interact with E2 enzymes, such as UbcH7 and UbcH8 
(13). Originally, E3 ligases were thought to be constitutively active, however, after 
further investigation, parkin activity was proposed to be governed by autoregulation, 
post-translational modification, such as ubiquitination or/and phosphorylation (14). Many 
putative substrates have been identified for parkin such as synphillin-1 (15), Pael-R (16), 
cyclin E (17) and several others. A popular hypothesis for parkin function is that it is 
fundamentally important for regulating appropriate levels of its protein substrates, 
especially avoiding accumulations of aggregate-prone substrates such as alpha-synuclein, 
Aβ peptide and Huntington protein (13). These aggregate-prone substrates of parkin, such 
as synphillin-1 and alpha-synuclein, with Ub and parkin itself have all been identified 
immunopositive in nigral cell Lewy bodies (15). Recent studies show a role for parkin in 
mitochondrial regulation, and its importance in retaining the mitochondrial DNA 
integrity by  
   7
  
 
  
Figure 1.3 Domain topology of the E3 ligase parkin protein. Parkin is a 465 residue 
protein and is composed of six domains. It has an N-terminal Ubiquitin-like domain 
(UbLD), which was structurally solved by NMR. Following the UbLD, is the unique 
parkin domain (UPD). RING0 and RING1 (really interesting new gene) are next in the 
sequence, followed by an In-Between RING (IBR) domain, which was also 
structurally solved by NMR spectroscopy. The most C-terminal domain is the RING2 
domain. Unlike the IBR and RING domains, the UbLD and the UPD domains do not 
coordinate two zinc ions. The ribbon diagrams of the UbLD and IBR were made using 
PyMOL and the PDB for parkin UbLD is 1IYF, and for parkin IBR is 2JMO.  
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promoting repair and by protection from reactive oxidative stress (18). Parkin has also 
been reported to bind tightly with microtubules for stabilization and quality control 
purposes, and interestingly, the microtubule network is crucial for another type of protein 
degradation mechanism known as aggregsomal degradation (19). The multiple roles of 
parkin in different cellular processes are still being investigated and this is an important 
aspect to appreciate especially when considering the outcome of pathogenic mutations on 
parkin. 
 
1.3.2 N-terminal ubiquitin like domain of the parkin protein 
  UbLD proteins are often found within multidomain proteins and the function of 
each UbLD within the USP is still under investigation (20). Like Ub, they possess the β-
grasp fold which has a hydrophobic face on the solvent exposed side of the β-sheets 
(Figure 1.4). What is unique to UbLD proteins, compared to the Ub molecule, is that they 
are unable to be conjugated to the lysine residue of a substrate protein because they lack 
the C-terminal glycine. Not to be confused with Ub-like domains, SUMO, ISG15, 
NEDD8 are examples of free Ub-like proteins that are covalently attached to substrates 
utilizing the same mechanism of Ub conjugation. The parkin N-terminal UbLD has 30% 
identity and 62% homology with the human Ub molecule (21) (Figure 1.4). The function 
of the UbLD is thought to be a recruitment domain for substrate recognition. It has been 
previously shown to interact with o-glycosylated alpha-synclein, an aggregation prone 
protein found in Lewy bodies; S5a, a proteasomal subunit; Eps15 an endocytosis 
involved protein; and ataxin-3, a DUB enzyme (2, 22, 23).   
   9
  
  
Figure 1.4 Structural and sequence comparison between the human Ub and 
parkin UbLD molecule. A) Both the parkin UbLD (left) and Ub (right) molecule 
share the beta-grasp fold which consists of 5 β-sheets and 2 α-helices. B) The parkin 
UbLD and human Ub sequence share 30% sequence identity, which is indicated with 
a red background. The ribbon diagram was created in PyMOL and the PDB for the 
parkin UbLD is 1IYF and human Ub is 1UBQ.  
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1.3.3 Autosomal recessive juvenile Parkinsonism is linked to the PARK2 gene 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease 
next to Alzheimer’s disease. The usual age of onset for PD is past the age of 50, however, 
there are approximately 5-10% of PD patients that have the misfortune of being 
diagnosed at a very early age. Acquiring the disease before the age of 40 is uncommon 
compared to the idiopathic late-onset form of the disease and is labeled as early-onset PD 
(10). Within this group of early-onset PD patients, a small group will have inherited it in 
an autosomal recessive fashion with complete penetrance. Autosomal Recessive Juvenile 
Parkinsonism (ARJP) affects men and women equally and its prevalence across various 
regions seems to be similar. The pathogenic characteristic of many idiopathically 
contracted patients include cytoplasmic insoluble protein aggregate, known as Lewy 
bodies (13). However, Lewy bodies are infrequently presented in parkin linked ARJP 
patients (24, 25). 
ARJP exhibits locus heterogeneity; there are five known monogenic mutants that 
are linked to the same disease phenotype and same inheritance pattern. The most 
common form of ARJP arises from PARK2 gene mutations, which codes for the parkin 
protein, and accounts for 50% of early-onset PD (26). Initial ARJP disease cases were 
characterized in Japanese families and were mostly caused by large exon deletions, but as 
the search for parkin-linked ARJP patients progressed, more single amino acid 
substitutions were characterized as disease mutations (21). These mutations were found 
throughout the PARK2 gene with a concentration of missense type mutations occurring 
in the RING1-IBR-RING2 C-terminus region (14, 27) (Figure 1.5).  
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1.4 Ataxin-3 
1.4.1 ATXN3 gene topology 
The gene that encodes for the ataxin-3 protein is called ATXN3 and is located on 
chromosome 14 (14q24.3-q32) (28). The human ATXN3 gene is approximately 48 Kb 
and is composed of 11 exons (29). There is a CAG trinucleotide repeat located within 
exon 10 that is prone to unstable expansions which cause neurodegeneration when the 
repeat number passes a threshold of >45 (29). Meanwhile, wild-type alleles can range 
from 11 to 44 CAG trinucleotide repeats (30). 
 
1.4.2 Ataxin-3 domain architecture 
The ataxin-3 protein has often been described as having unique domain topology 
due to the arrangement and number of Ubiquitin Interacting Motif (UIM) regions it 
possesses. Ataxin-3 is composed of an N-terminal catalytic Josephin domain, spanning 
residues 1-170 (Figure 1.6). The Josephin domain contains the catalytic cysteine (Cys14) 
that is required for its DUB activity. Following the folded Josephin domain are two 
tandem UIM regions, (UIM1, UIM2). UIM1 spans residues 224-243 and UIM2 spans 
residues 244-263. Following UIM2, there is a variable glutamine tract that can vary from 
11 to 44 repeats, which are non-disease causing lengths (30). At the C-terminus of ataxin-
3, following the poly-glutamine tract, there is a third UIM that spans residues 331-348, 
(UIM3) (Figure 1.6).  
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Figure 1.6 Schematic of the domain topology within the ataxin-3 DUB enzyme.  
Ataxin-3 consists of 5 distinct regions: the N-terminal catalytic Josephin domain 
(residues 1-170); two UIM regions (residues 224-243 and 244-263); a variable poly-
glutamine expansion that can consist of 11-44 residues for a non-disease state; and a 
C-terminal UIM region (residues 331-348). The N-terminal Josephin domain was 
structurally determined by both NMR spectroscopy and X-ray crystallography. The 
ribbon diagram was made using PyMOL and the PDB for ataxin-3 Josephin domain is 
1YZB.  
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1.4.3 Ataxin-3 expression, splice isoforms, subcellular localization and function 
The normal non-expanded form of human ataxin-3 is approximately 42 kDa, 
depending on the glutamine tract variability, and is expressed ubiquitously in many 
tissues including neuronal tissue. Ataxin-3 is predominantly a cytoplasmic protein based 
on immunohistochemical studies in various human neuronal cells (31). The mechanisms 
to regulate the expression of the ATXN3 gene are unclear, due to the variation at the 3’ 
untranslated region (UTR) and the lack of study in the 5’ UTR (29).  
Ataxin-3 functions as a deubiquitinating (DUB) enzyme, and falls under the 
Josephin gene family of DUB proteases because of its sequence homology with other 
Josephin genes (6). It has a preference to detach Lys63 linked poly-Ub chains, in vitro 
(32-34). The ataxin-3 protein participates in the ubiquitin-signalling pathway based on 
three pieces of evidence; (a) it is composed of a catalytic Josephin domain which has a 
DUB function, (b) it has three UIM sites involved in poly-Ub and UbLD interactions, and 
(c) it has many binding partners involved in the proteasomal pathway such as VCP 
(valosin-containing protein) (35), E6,AP (Ubiquitin ligase E3A) (36), and parkin (37). 
However, ataxin-3 is not restricted in participating with just the USP, it has also been 
found to play a role in DNA repair and ERAD (endoplasmic reticulum associated 
degradation) (38, 39). 
Ataxin-3 has been shown to have over 50 splice variants but only two have been 
extensively characterized and found to be expressed in a tissue specific manner. One of 
the splice variants encodes the full-length sequence which includes all three UIM sites. 
The other splice variant lacks the C-terminal third UIM site but includes the 
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polyglutamine stretch of ataxin-3 (40, 41). In human and murine brain, the splice 
variant encoding three UIM sites is the predominant isoform (40).  
 
1.4.4 Ubiquitin interaction motif 
Poly-Ub binding assays involving the human proteasomal subunit, S5a, were used 
to identify the UIM, though at the time it was originally known as the pUB motif (42). 
The UIM is one of fifteen identified protein groups dedicated to Ub or/and UbLD 
recognition. Interestingly, the Ub-recruitment domains vary in size and their three-
dimensional fold suggesting that Ub can accommodate an interaction for many domains, 
such as the UBA (Ubiquitin-Associated), DUIM (Double-sided Ubiquitin Interacting 
Motif), and CUE (Coupling of Ubiquitin conjugation to Endoplasmic reticulum 
degradation) (43). All of the Ub recruitment domains have weak binding affinities to 
mono Ub, in the 100 µM to 2 mM range, determined by either NMR, ITC (Isothermal 
Titration Calorimetry) or SPR (Surface Plasmon Resonance) methods (43).  
One of the first reviews that provided analysis of the identified UIM containing 
proteins reported that the UIM is composed of twenty residues and contain a conserved 
acidic stretch of approximately four residues prior to a series of highly conserved alanine 
and serine residues (44) (Figure 1.7).  The same group also noticed that many proteins 
containing the UIM regions often have more than one UIM site and can present itself in a 
wide variety of proteins with roles in endocytosis, proteasomal substrate recruitment, and 
DUB function (44). Further investigation of the UIM sequences sparked notice of an 
interesting trend of alternating large-small-large-small-large residues in between the two 
   16
  
  
Figure 1.7 Sequence alignment of the ubiquitin interacting motif of human 
proteins. Selected human proteins (ataxin-3, Eps15, Epsin1 S5a, Rap80) containing 
ubiquitin-interacting motifs (UIM) have their UIM sequences aligned. The protein 
name, UIM position, residue position, and the number of residues within the 
identified UIM is indicated on the left of the sequence. The motif consists of 
approximately 20 residues, starting with an N-terminal acidic stretch (red) of 3 to 5 
residues followed by a hydrophobic stretch (pink). There is a conserved alanine and 
serine residue that borders the hydrophobic stretch within each UIM. This sequence 
alignment was created in JalView. 
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 acidic patches of the UIM sequences (45) (Figure 1.7). Although the UIM sites of 
most proteins have high sequence similarities between one another, it cannot be assumed 
that all UIM sites will interact to Ub or UbLD proteins (2).  
The UIM region containing UIM1 and UIM2 of ataxin-3, spanning residues 194-
261, has been reported to possess α-helical structures separated by a flexible linker by 
NMR studies (46). The structure of the two UIM site in Vps27, a yeast protein involved 
in vacuolar protein sorting, was also characterized to have a helical conformation by X-
ray crystallography, NMR spectroscopy and circular dichroism (45, 47, 48). These are 
just two examples of structurally determined UIM domains that are helical. Although 
structures of other UIM domains have yet to be determined they are also thought to be α-
helical in structure (43). It has been reported that the helical-type of Ub binding domain, 
such as the UIM, DUIM and CUE are all thought to bind to the same site on Ub on its 
Ile44 hydrophobic patch (43). 
 
1.4.5 Polyglutamine expansion in ataxin-3 causes Machado Joseph Disease 
Polyglutamine diseases are characterized by protein misfolding leading to 
intracellular or intranuclear aggregate formation, caused by long repeats of CAG 
trinucleotides encoding for a poly-glutamine expansion, which eventually lead to 
neurodegeneration. The ataxin-3 protein is one of ten identified polyglutamine diseases 
which causes Machado Joseph Disease (MJD) (49) when its polyglutamine stretch is 
expressed passed a threshold of >45 residues. MJD is the most common dominantly 
inherited ataxia. Its name ‘Machado-Joseph’ originates from observations of two Azorian 
families that presented the disease in the 1970s (50). Interestingly, MJD patients exhibit a 
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wide variation of clinical presentations of parkinsonism characteristics, progressive 
external ophthalmoplegia, difficulty talking and difficulty swallowing (49). The affected 
brain areas based on MRI and neuroimaging studies indicates that the pons, midbrain, 
fourth ventricle, and basal ganglia are all affected in addition to the cerebellum and 
brainstem (51-55). The polyglutamine tract lies between the second and third UIM site of 
the ataxin-3 protein. The study of polyglutamine disease causing proteins are often 
focused on understanding the protein conformation of the wildtype and disease state 
proteins to understand how it relates to protein misfolding and aggregation. The difficulty 
in performing biophysical and biochemical analyses comes from issues in purifying great 
yields of the disease state proteins that are soluble in solution (56).  
 
1.5 Scope of Thesis 
Parkin and ataxin-3 are both multidomain proteins that play a role in the USP. 
The aim of this work was to characterize the interaction between the recruitment domains 
of these proteins. Investigation of their interaction will improve the overall understanding 
of the biological roles these proteins contribute to the USP. There has been evidence to 
support the direct interaction between ataxin-3 and parkin through affinity binding 
assays, however, a detailed analysis of the residues that are involved, the mechanism and 
the affinity of the interaction have not been deduced (23).  
The goals of this thesis were: 
1) Determine the binding surface on parkin UbLD when ataxin-3 is bound to it. 
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2) Determine which combination of UIM region(s) in ataxin-3 are crucial for the 
interaction with the parkin UbLD.  
3) Propose a biologically relevant binding model for parkin and ataxin-3.  
4) Address the biological consequence of structurally benign ARJP substitutions and 
the interactions of these proteins with ataxin-3.  
To address the goals, 1H-15N HSQC titrations and chemical shift perturbation 
analyses were carried out using NMR spectroscopy to reveal residues that participate in 
the binding interface, identify which UIM sequences participate in the interaction with 
the UbLD and determine the binding affinity of these interactions. Analysis of the 
binding affinities between the UbLD and various ataxin-3 UIM constructs, with either C-
terminal UIM deletions or ‘functional knockouts’ of the UIM sites, assisted in proposing 
a type of binding mechanism that could explain the parkin ataxin-3 interaction. The same 
1H-15N HSQC titration experiments were utilized for the interaction study between ARJP 
substituted UbLD proteins and ataxin-3194-361, to determine how their structures are 
affected by the substitution, and determine whether the ARJP substitution perturbed the 
affinity of the interaction. A four-part hypothesis was proposed; a) the parkin UbLD has a 
unique ataxin-3 binding site, b) all three UIMs in ataxin-3 are important for parkin 
binding, c) parkin uses a multivalent binding mechanism to recruit ataxin-3, d) 
structurally benign ARJP mutations in the parkin UbLD will decrease the binding affinity 
to ataxin-3. 
There is growing evidence to support that ataxin-3 and parkin interact with each other 
to regulate both of their catalytic function (23, 37). This body of work highlights the 
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interaction mechanism, binding sites, and ARJP substitutions in the interaction studies 
between parkin and ataxin-3. 
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Chapter 2 
CHARACTERIZATION OF THE INTERACTION BETWEEN THE PARKIN 
UBLD AND THE UIM REGION OF ATAXIN-3 
2.1 Introduction 
Parkin and ataxin-3 are both multi-domain proteins that function in the ubiquitin 
signaling pathway (USP). The roles of the proteins are opposing. Parkin is an E3 
ubiquitin ligase that is responsible in attaching ubiquitin (Ub) on a specific set of 
substrates, whereas, ataxin-3 is a deubiquitinating (DUB) enzyme which acts to remove 
Ub moieties from poly-ubiquitin chains (1). There is growing interest in the USP as 
protein misfolding diseases are linked to these pathways. The concern is that when 
disease mutations or malfunctions in the regulators of the USP ensue, the protein 
homeostasis in the cell becomes disrupted to seed cellular aggregation and cell death. 
Recently, it has been shown that the direct interaction of these two proteins can regulate 
their catalytic function and turnover via autophagy (1). Interaction studies between parkin 
and ataxin-3 have been previously investigated by GST binding assays and co-
immunoprecipitations, however, the binding interface and mechanism for the interaction 
remains unknown (1). Some difficulties in interpreting this interaction result from 
purification problems of the unstable full-length parkin, and the lack of solved structures 
of the full-length parkin and ataxin-3 proteins, which limits the prediction of docking 
sites of the interaction. The strategy employed to overcome this obstacle was to identify 
the specific region(s) of interaction and purify only these critical domains required for the 
interaction. By isolating the regions of recruitment from parkin and ataxin-3, the 1H-15N 
HSQC spectra will be easier to analyze and resonances can be unambiguously followed 
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in an NMR titration, which was the main source of data collection. Based on 
deubiquitination assays with a C-terminal deletion of the three Ubiquitin Interacting 
Motifs (UIM) within ataxin-3 (Δ194-361), the C-terminus of ataxin-3 was found not to be 
important for its DUB activity. It was then postulated the UIM region functions as a 
recruitment domain for ubiquitin chains on substrate proteins and may be important for 
positioning the ubiquitin chain for cleavage by the DUB catalytic portion of ataxin-3. The 
parkin UbLD has 30% sequence identity with ubiquitin and possesses a similar 3D 
structure, which made it a potential candidate for interactions with the UIM region of 
ataxin-3 (3). The UIM regions of Eps15, an endocytic protein, and S5a, a regulatory 19s 
subunit, have been shown to bind to the hydrophobic patch of the UbLD by NMR 
chemical shift perturbation studies. However, a docking site has not been determined for 
the ataxin-3 UIM region (2). Unlike the Eps15 and S5a protein, which only have two 
UIMs, the ataxin-3 gene encodes a unique arrangement of three UIM regions spanning 
ataxin-3 residues 224-243, 244-263, 331-348 for UIM1, UIM2, and UIM3, respectively. 
Currently, there is controversial evidence whether all three UIMs are important (3, 4, 5) 
for the proper functioning of ataxin-3.  
In this work, the aims were to identify the binding site on the parkin UbLD for the 
UIM region of ataxin-3194-361, to calculate the binding affinities, to determine which UIM 
from the C-terminus of ataxin-3 interacts with parkin, and use this data to predict what 
type of binding mechanism is employed for their interaction. The characterization of the 
binding interaction between ataxin-3 and parkin will be utilized for predicting how 
Autosomal Recessive Juvenile Parkinsonism (ARJP) substitutions might influence 
binding. 
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2.2 Materials and Methods 
2.2.1 Parkin ubiquitin-like domain 
 The DNA encoding human parkin ubiquitin-like domain (1-77) was previously 
inserted into the NdeI and BamHI sites of the pET44a vector (Novagen) (2). The parkin 
UbLD constructs were verified by DNA sequencing (Robarts Sequencing Facility). 
 
2.2.2 Ataxin-3 ubiquitin interacting motifs 
The cDNA encoding full-length human ataxin-3 construct was a generous gift 
from Dr. Edward Fon (McGill, Montreal, Quebec). The ataxin-3 cDNA contained a 14 
residue polyglutamine tract as well as an N-terminal hexa-histidine tag. Site-directed 
mutagenesis was previously used to incorporate a TEV cleavage site to allow for removal 
of a 6-residue N-terminal histidine tag from ataxin-3 constructs. The His-tagged ataxin-
3194-361 construct, containing all three UIM regions, was inserted into the BamHI and 
XhoI sites of the pET21a vector (Novagen). Site-directed mutagenesis was also used to 
generate a C-terminal deletion construct, consisting of residues 194-261, by encoding a 
stop site prior to the poly-glutamine stretch of ataxin-3. To create a single UIM construct 
of just the N-terminal UIM194-244, the same approach was executed by using site directed 
mutagenesis to make a stop site prior to the DNA sequence encoding the second UIM. 
 The individually intact UIM genes were synthesized by DNA2.0 in their house 
pJexpress414 vector and cloned into the NdeI and XhoI sites (Fig. 2.1). The conserved 
serine, (residues 236, 256 and 347 within UIM1, 2, and 3) and hydrophobic stretch in the 
core UIM sequence (residues 229-243, 249-253, 340-344) were substituted to alanine 
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residues and designed in the computer program Gene Designer 2.0. All genetic 
elements were identical to the wild-type ataxin-3 constructs mentioned above. Three 
vectors were ordered to experiment with individual functional UIMs; functional knockout 
of UIM I/II, functional knockout of UIM II/III, and functional knockout of UIM I/III. 
DNA sequencing was carried out to ensure the correct sequence of the ataxin-3 UIM 
genes (Robarts Research Institute). 
 
2.2.3 Expression and purification of the parkin ubiquitin-like domain 
 The human parkin UbLD was overexpressed in BL21(DE3) Codon PlusRIL 
Escherichia coli strain and was cloned without an affinity tag.  The bacterial culture was 
diluted 1:100 volume ratio in LB media, and grown at 37°C until an A600 of 0.6-0.7 was 
reached. The culture was grown with constant shaking overnight at 16°C after induction 
of expression by the addition of 1 mM isopropyl 1-thio-β-D-galactopyranoside. The 
starter culture and large bacterial cultures contained the antibiotic ampicillin (50 µg/mL). 
Cells were lysed with either an EmulsiFlex-05 homogenizer (AVESTIN) or French press 
and centrifuged at 132380 g for one hour. The cell homogenate was filtered through a 
MILLEX HV 0.45 µm filter unit (MILLIPORE) before loading onto a HiTrap Q XL 
column, using a AKTA FPLC system (GE Healthcare). The binding buffer contained 25  
   31
  
 
 
 
 
 
 
  
E coli RBS
pJexpress 414
  (DNA 2.0)
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T7/lac
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(Nde I, XhoI)
T7 Terminator
A
Figure 2.1 Diagrammatic representation of the DNA 2.0 pJexpress414 
vector. The individually intact UIM genes were inserted into the NdeI and XhoI 
sites of the pJexpress 414 vector. The genetic elements such as the hexa-His tag 
and the TEV cleavage site matches the genetic elements for all the previously 
mentioned ataxin-3 protein constructs. The multiple cloning site was optimized 
for E. coli expression. All of the genetic elements and multiple cloning site 
sequence were designed in the computer program Gene Designer 2.0. 
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mM Tris and 1 mM EDTA at pH 9.0, and the elution buffer contained 25 mM Tris, 1 
mM EDTA and 1 M NaCl at pH 9.0. The protein eluted in the flowthrough fractions and 
was further purified on a size exclusion column (G75) at 4°C in 50 mM Na2HPO4, 150 
mM NaCl, 1 mM EDTA, 1 mM DTT, at pH 8.0 with a flowrate of 6ml/hour. The 
integrities of all ARJP substituted proteins were confirmed previously using electrospray 
ionization mass spectrometry (UWO Biological Mass Spectrometry Laboratory) (2). 
 
2.2.4 Expression and purification of ataxin-3 ubiquitin interacting motifs 
All six human ataxin-3 UIM constructs were overexpressed in a BL21(DE3) 
Codon PlusRIL Escherichia coli strain. The bacterial culture was diluted 1:100 volume 
ratio in LB media, and grown at 37°C until an A600 of 0.6-0.7 was reached. The culture 
was grown with constant shaking overnight at 16°C after induction of expression by the 
addition of 1 mM isopropyl 1-thio-β-D-galactopyranoside. The starter culture and large 
bacterial cultures contained the antibiotic ampicillin (50 µg/mL). Cells were lysed with 
either an EmulsiFlex-05 homogenizer (AVESTIN) or French press and ultracentrifuged 
at 132380 g. The cell homogenate was filtered through a MILLEX HV 0.45 µm filter unit 
(MILLIPORE) before loading onto a Ni-NTA fast protein liquid chromatography affinity 
column (GE healthcare). The loading buffer contained 50mM Na2HPO4, 500nM NaCl, 
10mM imidazole at pH8, and the elution buffer was identical except with the addition of 
500mM imidazole. The protein samples were dialyzed overnight at 4°C in the loading 
buffer with an addition of TEV protease (1.2mg/1L bacterial preparation) for cleavage, 
and reloaded onto the Ni-NTA column. Cleaved UIM proteins came off in the 
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flowthrough. All six of the ataxin-3 UIM constructs were purified using the same 
protocol. 
 
2.2.5 NMR Spectroscopy titration experiments 
All 1H-15N Heteronuclear Single Quantum Coherence (HSQC) NMR experiments 
were performed on a 600 MHz Varian Inova spectrometer (BioNMR Facility, UWO). All 
protein samples were extensively dialyzed into 11 mM KH2PO4, 150 mM NaCl, 1 mM 
EDTA, 1 mM dithiothreitol, at pH 7. Imidazole (100 µM) was added in the final NMR 
sample to serve as a pH indicator. All spectra were recorded at 25°C. Chemical shift 
perturbation upon binding between protein samples were monitored and fit with either a 
non-linear regression global fit for a 1:1 binding model or a 3:1 multivalent global fit 
with equivalent affinities.  
 
Consider, ! +   ! ⇌ !" 
P - protein 
L - ligand 
PL - protein-ligand complex 
 
The equation that was used for non-linear regression global fitting for a 1:1 binding site 
was, 
!" =    (!" + ! + !!) − (!" + ! + !!)2 − (4 + ! + !")2  
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! = ! ∙ ! ∙ (!" !") 
PL - Protein-Ligand Complex 
Pt - Total Protein 
X - Added Ligand Concentration 
KD - Dissociation Constant (same units as Pt) 
n - number of identical sites 
B - Normalization Factor 
The normalization factor is required for the global fit of the binding curves. Since the 
chemical shift differences of different resonances that change upon addition of ligand are 
not identical. 
 
For a 3:1 multivalent model, consider, 
 ! +   ! ⇌ !!!               K1 ! +   ! ⇌ !!!               K2 ! +   ! ⇌ !!!               K3 
 
Where PL1, PL2, PL3 are three different sites on the ligand (ataxin-3) that the protein can 
bind. 
P - protein 
L - ligand 
PLx - protein-ligand complex 
 
 
 
Assuming the ligand binds to each site with equal affinity (ie. K1 = K2 = K3 = KD), then 
the equation used to globally fit a three multi-site binding model is,  
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 !" = ! ∙ !" + ! ∙ ! + !! − (! ∙ !" + ! ∙ ! + !!)2 − (4 ∙ !2 ∙ ! ∙ !")2 ∙ !2  
 
 ! = ! ∙ ! ∙ (!" !") 
 
The computer programs used to fit data were Prism 4 and NMRViewJ version 8.0.rc4. 
Titration experiments that were performed are listed (Table 2.1). Protein samples were 
sent to the Amino Acid Analysis facility (Sick Kids Hospital, Toronto, ON) for acquiring 
accurate protein concentration values. Details regarding the concentrations of 15N-labeled 
proteins as well as titrant proteins can be found in the results section. 
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Table 2.1 The protein combinations used in the 1H-15N HSQC titration experiments 
 
*  - indicates the ataxin-3 UIM constructs that are full-length (including residues 194-
361) but with only one functional UIM with the other two UIMs are ‘functionally 
knocked out’ by alanine substitutions. In this context, functional is defined as being able 
to retain interaction with the UbLD. In contrast, ‘functionally knocked out’ means that 
conserved residues in the UIM sequence have been substituted by alanine residues and 
can no longer interact with the UbLD. 
  
15N Isotopically Labeled Unlabeled Protein (Titrant) 
Parkin UbLD Ataxin-3 UIM123 194-361 
Parkin UbLD Ataxin-3 UIM12 194-261 
Parkin UbLD Ataxin-3 UIM1 194-244 
Parkin UbLD Ataxin-3 UIM3*194-361 
Parkin UbLD Ataxin-3 UIM2*194-361 
Parkin UbLD Ataxin-3 UIM1*194-361 
Ataxin-3 UIM123194-361 Parkin UbLD 
Ataxin-3 UIM12194-264 Parkin UbLD 
Ataxin-3 UIM123194-361 Ubiquitin 
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2.3 Results 
2.3.1 Molecular biology, expression and purification of parkin ubiquitin like domain 
The human parkin UbLD gene had previously been inserted into the NdeI and 
BamHI sites of the pET44a vector (Novagen) (3). The overexpression of the UbLD in 
BL21(DE3) Codon PlusRIL Escherichia coli strain was induced with 1mM IPTG and the 
overexpressed protein band can be seen just below the 10 kDa molecular weight ladder, 
as expected since the molecular weight of the UbLD is 8824 Da (Figure 2.2). The rate of 
protein separation of the sizing column was 6ml/hr and the fractions containing pure 
UbLD protein elutes from the column between hours 65-75 or shown as lanes 7-10 in 
Figure 2.2B. Purified proteins were checked on an SDS-PAGE gel for purity. 
 
2.3.2 Molecular biology, expression, and purification of ataxin-3 UIM123194-361 and 
other ataxin-3 constructs 
The ataxin-3 UIM123194-361 construct with three intact UIM regions was 
successfully inserted into the BamHI and XhoI sites of the pET21a vector (Novagen), 
previously done. Site-directed mutagenesis was then used to incorporate a TEV cleavage 
site to allow for the removal of a 6-residue N-terminal histidine tag from ataxin-3 
construct.  
All of the ataxin-3 protein constructs were overexpressed in a BL21(DE3) Codon 
PlusRIL Escherichia coli strain. All ataxin-3 protein constructs have the same genetic 
elements, an N-terminal six histidine-tag followed by a TEV cleavage site upstream of 
the ataxin-3 UIM gene. Two Ni2+-NTA FPLC column steps were completed to obtain a 
tag free protein that just includes pure fractions of ataxin-3 UIMs (Figure 2.3). In  
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Figure 2.2 SDS-PAGE of parkin ubiquitin-like domain expression 
and purification. A) Lanes 1 and 2 are the pre-induction and post IPTG 
induction expression test for the UbLD. Lane 3 is the lysate, prior to 
loading onto the HiTrap Q XL column and lane 4 is the flow through off 
the column. Lane 5 is the molecular weight ladder. Lane 6 is the elution 
fraction off the Q XL column. Lanes 7-9 show fractions collected from 
the G75 sizing column. B) The SDS-PAGE of protein fractions collected 
off of the G75 sizing column. The UbLD, which has a calculated 
molecular weight of 8824 kDa, migrates just below the 10kDa molecular 
ladder band. Both gels were stained in Coomassie brilliant blue. 
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Figure 2.3 Purification of ataxin-3 UIM123194-361. A) The three lanes are showing 
the first elution fractions off of the Ni2+-NTA column of the ataxin-3 purification, 
prior to TEV cleavage of the hexa-histidine tag. The yellow arrow indicates the 
overexpressed His-tagged ataxin-3 UIM123194-361 protein. B) SDS-PAGE showing 
the elution fraction of the second part of the ataxin-3 purification. This fraction was 
eluted from the second Ni2+-NTA column pass through, following TEV cleavage 
overnight. C) The lane highlighted in the red box is showing the degradation of 
ataxin-3 UIM123194-361 construct over two weeks time at 4°C. 
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between the two Ni2+-column steps, the protein was extensively dialyzed in a low 
imidazole buffer with TEV specific protease to cleave the N-terminal six histidine tag 
from the ataxin-3 protein construct. His-tagged ataxin-3 UIM123194-361 migrates to 
greater than 25 kDa, but after the TEV cleavage step, the ataxin-3 UIM123194-361 protein 
migrates just short of 25 kDa (Figure 2.3). After purification of the ataxin-3 UIM region, 
it was observed that this region was prone to degradation (Figure 2.3).  
 
2.3.3 Ataxin-3 UIM123194-361 confers a docking site on the hydrophobic patch of the 
parkin UbLD 
Titration experiments monitored by 1H-15N HSQC spectra were performed with 
15N-labelled parkin UbLD and unlabeled ataxin-3, to identify the binding site of ataxin-3 
on the UbLD. The 1H-15N HSQC spectrum of 15N UbLD in the absence of binding 
partner displays disperse peaks in the proton dimension, indicative of a well-folded 
protein. Each peak represents the amide proton correlated to its amide nitrogen, thus, 
each amino acid in the sequence, except proline residues, will have a corresponding 
resonance. Resonances that shift upon titrations of a binding partner are indicative of 
nuclei experiencing a local environmental change, which are the residues involved in the 
interaction. The binding site on parkin was determined by measuring the absolute change 
in chemical shift (in ppm) of the UbLD resonances with titrations of up to 6 equivalents 
of ataxin-3 UIM123194-361 construct (Figure 2.4). The resonances that shifted greater than 
0.5 standard deviation above the average chemical shift were mapped on the surface of the 
UbLD (Figure 2.5). The backbone assignments of both parkin UbLD and most residues of 
the ataxin-3 UIMs construct were previously determined, and all of the resonances were  
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Figure 2.4 NMR chemical shift perturbation data of parkin UbLD upon 
ataxin-3 UIMs194-361 binding. Chemical shift perturbation map of UbLD by 
measuring the absolute change in magnitude of the peak shifts that occurs after 
addition of 6 eq. of ataxin-3. The concentration of the UbLD protein sample was 
105 µM. The absolute change in magnitude of the resonance shifts were 
calculated using the equation, ((0.2 × ΔδN2) + ΔδH2)1/2.  The dotted green line 
indicates 0.5 S.D. above the average chemical shift perturbation value. The 
residues on parkin that display more than 0.5 standard deviation above the average 
chemical shift are V3, N8, H11, F13, V15, A46, K48, E49, V56, I66, V67, H68, 
V70, Q71, and R75. 
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Figure 2.5 Surface and ribbon representation of the binding surface for ataxin-
3194-361 on the parkin ubiquitin like domain. A) A surface representation, coloured 
in pink, of where ataxin-3194-361 binds on the UbLD. The residues that displayed more 
than 0.5 standard deviation above the average chemical shift were mapped on the 
surface of the UbLD which is highlighted in pink. B) The seven amino acid side 
chains that displayed the greatest chemical shift perturbations upon addition of 6 
equivalents of the full UIMs ataxin-3 construct are shown. The individual beta 
strands and alpha helices from the beta-grasp fold blanketing over the alpha helix are 
labeled. 
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accounted for when a standard 1H-15N HSQC spectra of the UbLD1-77 and ataxin-3 
UIM123194-364 construct were collected (3). The residues on parkin that display greater 
than 0.5 standard deviation above the average chemical shift were Val3, Asn8, His11, Phe13, 
Val15, Ala46, Lys48, Glu49, Val56, Ile66, Val67, His68, Val70, Gln71, and Arg75 (Figure 2.4). 
Most of these residues are found on the solvent exposed hydrophobic patch of the UbLD, 
as highlighted in pink (Figure 2.5). Ala46 and Ile66 are two of the hydrophobic residues on 
the hydrophobic patch of parkin that are influenced by ataxin-3 UIM123194-361 binding. 
From the perspective of the parkin protein, residues participating in the interaction are 
dominated by hydrophobic amino acid residues (Leu61, Ile66, Phe13), followed by basic 
amino acid residues (Lys48). The binding site on the UbLD is composed of residues from 
multiple secondary structures, suggesting that the three-dimensional fold of this domain 
must be intact to expose the docking site for ataxin-3. 
 
2.3.4 Parkin UbLD interacts with all three ubiquitin interacting motifs from ataxin-3 
1H-15N HSQC titration experiments were utilized to investigate which UIM from 
ataxin-3 participates in the interaction with the UbLD. For each NMR titration 
experiment, 6-8 titration points were collected by incrementally adding unlabeled UbLD 
to 15N-labeled ataxin-3 UIM123194-361. At each titration point, a standard 1H-15N HSQC 
experiment was collected. By overlaying the spectra taken from each titration point, the 
resonances that were ‘shifting’ on the ataxin-3 could be identified. Many NMR titration 
experiments were utilized to systematically identify whether UIM1, UIM2 and/or UIM3 
participate in the interaction with parkin. However, the experiment involving 15N-labeled 
ataxin-3 UIM123194-361 titrated with unlabeled UbLD1-77 was the only experiment that 
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revealed whether any or all of the three UIM regions of ataxin-3 were interacting with 
the UbLD.  
The backbone assignments of the ataxin-3 UIMs construct were previously 
assigned, by previous graduate student Dr. Safadi, and all of the resonances were 
accounted for when collecting a standard 1H-15N HSQC spectra of the ataxin-3 
UIM123194-361 construct. The dissociation constant from the perspective of each UIM 
were globally fitted to a 1:1 non-linear regression fit, KD, UIM1= 2092±654 µM, KD, UIM2= 
1071±263 µM, KD, UIM3= 1975±368 µM (Figure 2.6). The dissociation constant for UIM1 
is in the same range within error for both KDs of the other two UIMs. Meanwhile, the KD 
between UIM2 and UIM3 are not in the same range within error, with UIM2 having a 
slightly tighter binding to the UbLD than UIM3.  The KD values were calculated solely 
based on the amide proton shifts, due to the greater magnitude of perturbation in the 
proton dimension as compared with nitrogen dimension (Figure 2.7). However, there was 
difficulty finding appropriate resonances from each UIM to measure chemical shifts 
from, due to the collapse of many resonances in the proton dimension of the 1H-15N 
HSQC spectrum of ataxin-3 UIM123194-361 protein alone, which is indicative of random 
coils in protein fold (Figure 2.7). From UIM1, residues A232, A234, D241 were 
followed, while in UIM2 only one residue (D248) could be unambiguously followed. In 
UIM3, amino acid residues S335, V344, and T345 were followed to obtain the KD 
(Figures 2.6, 2.7). Despite the collapse in the proton dimension of the spectrum, there are 
still other resonances from each UIM that are clearly identified to be shifting in response 
to additions of UbLD protein (Figure 2.7). The individual binding affinities of the UIM  
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Figure 2.6 Binding curves of the change in proton chemical shift of 
resonances from UIM1, UIM2, and UIM3 of ataxin-3 with titrations of 
parkin UbLD. Measurements were taken from NMR 1H-15N HSQC titration 
experiments with samples containing 15N ataxin-3 UIM123194-­‐361 (73µM) and 
additions of unlabeled UbLD (0, 58.7, 117.5, 235, 376, 470, 705, 940µM). The 
KD values are KD,UIMI = 2092±654 µM, KD,UIM2 = 1071±263 µM, and KD,UIM3 = 
1975±368 µM based on a global fit of non-linear regression analysis for 1:1 
binding. The corresponding amino acid residue of which the chemical shifts 
were measured are indicated to the right side of the binding curve. 
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Figure 2.7 Region of the 1H-15N HSQC spectrum of ataxin-3 UIM123194-361 
overlaid with a 1H-15N HSQC spectra of ataxin-3 UIM123194-361 with 12 
equivalents of parkin UbLD (blue). NMR data was collected with Varian 
INOVA 600 MHz NMR spectrometer with samples in a buffer containing 10 mM 
KH2PO4, 1 mM EDTA, 1 mM DTT pH 7.0 at 25°C (pH indicator, Imidazole). The 
starting concentration of 15N labeled ataxin-3 UIM123194-361 was 73µM and was 
titrated with up to 12 equivalents of UbLD. The red arrows indicate the direction 
of chemical shift changes upon UbLD additions for residues in UIM3. The yellow 
and green arrows indicate chemical shifting directions for UIM2 and UIM1, 
respectively. 
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regions are all in the millimolar range suggesting that UIM1, UIM2 and UIM3 are all 
able to make weak interactions with the UbLD.   
 The same experiments were repeated except with a 15N-labelled species of the 
ataxin-3 UIM12194-261 construct (containing only UIM1 and UIM2) with incremental 
titrations of the UbLD to greater than 10 equivalents. The fitting of the binding curve was 
poor due to not reaching saturation in binding of the isotopically labeled protein. The 
binding affinity for both UIM1 and UIM2 were in the same range within error of all three 
UIMs in the 15N ataxin-3 UIM123194-361 experiment, mentioned above. The dissociation 
constants were derived from considering chemical shift changes only in the proton 
dimension, amino acid residues from UIM1 used to obtain a KD, UIM1 = 3075±563 µM, 
were A232, A234, D241, residues from UIM2 to obtain a KD, UIM2 = ~15400±20000 µM, 
were solely based on residue D248. The deletion of the most C-terminal UIM and poly-
glutamine tract (14Q) clears up some of the congestion of resonances in the proton 
dimension of the 1H-15N HSQC spectrum. When comparing the ataxin-3 UIM12194-261 
spectrum with the ataxin-3 UIM123194-361 spectrum, many of the residues belonging to the 
third UIM or closely surrounding the motif, which are resonances that can only be found 
in the ataxin-3194-361 1H-15N HSQC spectrum, can be observed to experience chemical 
shift perturbations upon addition of the UbLD. Thus, the third UIM is participating in the 
interaction with the UbLD, along with UIM1 and UIM2. 
2.3.5 1H-15N HSQC experiments of 15N parkin UbLD with titrations of individually 
intact ataxin-3 support that all three UIM regions are able to interact with the UbLD 
To support the findings from the titration experiments involving 15N-labelled 
ataxin-3194-361 and UbLD additions, which showed that all three UIM regions were 
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participating in the interaction with the parkin UbLD, the complementary experiments 
were carried out. This involved overexpressing the individual functional UIM regions, 
and titration of these proteins into 15N-labelled UbLD. The conserved serine and 5 
hydrophobic core residues, both within the UIM region, were substituted for alanine 
residues to ensure that the UIM was no longer able to bind to the parkin UbLD. 
Comparisons of the UbLD 1H-15N HSQC spectrum alone overlaid with a 1H-15N HSQC 
spectrum of the UbLD with an addition of the most concentrated addition of ataxin-3194-
361 intact UIM1, UIM2 and UIM3 shows that there were many similarities between the 
resonances that experience a change in its chemical shift (Figures 2.8, 2.9, 2.10). Lys48, 
Glu49, and Ile66 displayed the greatest chemical shift change upon binding to the ataxin-3, 
and the corresponding resonances were consistently shifting in the same direction for 
each separate titration experiment for additions of either intact UIM1, UIM2, or UIM3 
constructs (Figure 2.9ADG, Figure 2.10). There were only local changes to the UbLD 
upon binding each UIM, as only a few residues shift upon titrations of UIM1, 2 or 3. 
Most of the resonances from the UbLD did not change upon titration of any of the UIM 
regions (Figure 2.8). One such resonance was Val29, which is buried beneath the beta-
grasp fold, was not perturbed by complex formation. It is proximal to Val17, another 
residue that was not perturbed greatly by complex formation with the UbLD (Figure 
2.9CFI). Although most of the residues of the UbLD behaved similarly upon UIM1, 2 or 
3 titrations, not all of the peaks shifted in identical magnitudes or direction (Figures 2.8, 
2.10). The absolute chemical shift perturbations were measured to derive the dissociation 
constant for each titration experiment. The dissociation constants were KD, intact UIM1 = 840  
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Figure 2.8 1H-15N HSQC spectra of 15N parkin UbLD overlaid with spectra 
following additions of functionally intact ataxin-3 UIM1*194-361 (A), UIM2*194-361 
(B), and UIM3*194-361 (C). NMR data was collected with Varian INOVA 600 MHz 
NMR spectrometer with samples in a buffer containing 10 mM KH2PO4, 1 mM 
EDTA, 1 mM DTT pH 7.0 at 25°C (pH indicator, Imidazole). The starting 
concentration of 15N labeled parkin UbLD was 100µM (for all three titrations) and 
was titrated with up to (A) 6.5, (B) 8,  (C) 7.9 equivalents ataxin-3, respectively. 
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Figure 2.9 Selected region of 1H-15N HSQC spectra of 15N parkin UbLD 
overlaid with HSQC spectra with incremental additions of functionally intact 
ataxin-3 UIM1*194-361 (A-C), UIM2*194-361 (D-F), and UIM3*194-361 (G-I). Spectra 
were collected on a Varian INOVA 600 MHz NMR spectrometer with samples in a 
buffer containing 10 mM KH2PO4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT pH 7.0 
at 25°C (pH indicator, Imidazole). The starting concentration of 15N labeled parkin 
UbLD was 100 µM (for all three titrations) and was titrated with up to (A) 6.5, (B) 8,  
(C) 7.9 equivalents ataxin-3, respectively. The similar behaviour for resonances of 
amino acid residues Lys48, Leu61 and Val29 for all three sets of titration experiments 
is shown. 
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Figure 2.10 NMR chemical shift perturbation data comparison of the parkin UbLD 
interaction with individual functional ataxin-3 UIM1*194-361 (black), UIM2*194-361 
(blue), and UIM3*194-361 (red). Chemical shift perturbation data of the UbLD was 
determined by measuring the absolute change in magnitude of peak shifts that occurred 
after addition of 6 eq. of ataxin-3. The absolute change in magnitude of the resonance 
shifts were calculated using the equation, ((0.2 × ΔδN2) + ΔδH2)1/2.  The dotted line 
indicates 0.5 S.D. above the average chemical shift perturbation value. The residues on 
parkin that display more than 0.5 standard deviation above the average chemical shift were 
K48, E49, I66, and H68. 
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± 189 µM, KD, intact UIM2 = 502 ± 41 µM, KD, intact UIM3 = 921 ± 165 µM (Figure 2.11). 
The absolute chemical shifts were measured following residues Lys48, Glu49 and Leu61 
for each titration experiment in order to generate binding curves. Other residues observed 
to shift were Val43, Glu64, and His68; corresponding experiment for which these residues 
were measured are found on Figure 2.11. The data collected from these three titration 
experiments support the finding that all three UIM regions of ataxin-3 are participating in 
the interaction with the UbLD. 
 
2.3.6 1H-15N HSQC experiments of UbLD with titrations of C-terminal deletions of 
UIM regions display an increase in binding affinity when all three UIM regions are 
present 
Resonances of the 15N UbLD displaying the greatest chemical shifts in the 1H-15N 
HSQC spectrum were measured (Figure 2.12, 2.13). After plotting the changes in 
chemical shift in response to increased concentrations of C-terminal deletion ataxin-3 
constructs, the dissociation constants were determined by a global fitting of the non-
linear regression analysis for a 1:1 binding curve.  
The dissociation constants obtained for the full UIM construct to 15N UbLD were 
235.7 ± 14.0 µM, and 221.7 ± 17.6 µM, in the nitrogen and amide proton dimension, 
respectively (Figure 2.13A). The interaction appears to be weaker when the third UIM is 
deleted, the KD values obtained for the ataxin-3 UIM12194-261 construct titrated into the 
15N UbLD were 422.5±25.8 µM, and 433.7±37.3 µM, in the nitrogen and amide proton 
dimension, respectively (Figure 2.13B). When only the most N-terminal UIM is available 
to interact  
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Figure 2.11 Binding curves of the absolute change in chemical shift of 15N 
UbLD with titrations of ataxin-­‐3	  UIM1*194-­‐361,	  UIM2*194-­‐361,	  and	  
UIM3*194-­‐361. The absolute chemical shifts take into consideration both the 
proton and nitrogen chemical shifts. The KD values are KDUIMI = 840.3±188.6 
µM, KDUIM2 = 502.3±41.4 µM, and KDUIM3 = 921.0±165.0 µM based on a global 
fit of non-linear regression analysis for 1:1 binding. The corresponding amino 
acid residue of which the chemical shifts were measured are indicated to the 
right side of the binding curve.	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with the UbLD, the KD was greater than 2 mM with a standard error of 400 µM (Figure 
2.7C). The poor fit of the binding curve can be attributed from not being able to saturate 
the UbLD with enough substrate. Another difficulty that arose was due to resonance 
behaviour, such as peak intensity changes, which made it difficult to distinguish the peak 
above noise of the HSQC. Therefore, some peaks could not be unambiguously assigned 
in order to track the changes in chemical shift. An example of this behaviour was seen by 
Arg75 (Figure 2.13C). The only residue that could be unambiguously followed for UIM1 
construct and gave the best fit was Lys48 (Figure 2.13C).  
Most of the residues that displayed large chemical shift changes are located on the 
fourth and fifth β-strand, such as Lys48 and Glu49 on the fourth β-strand, and Gln64, Ile66 
on the fifth β-strand. Other residues outside this region that shifted include residues 
Phe13, which resides at the N-terminus (2nd β-strand), and Arg75 located at the C-terminus 
tail of the UbLD. While these residues are not clustered in exactly the same regions, they 
all fall on the beta-grasp face of the UbLD (Figure 2.5). 
 
2.3.7 Modelling the binding mechanism of the ataxin-3 UIM123194-361 with UbLD using 
a multivalent binding mechanism 
The observations that all three UIM regions were participating in the interaction 
with parkin and that the greater the number of intact UIM regions correlates with 
strengthening the interaction led to the prediction that a multivalent binding mechanism 
could be employed by the UIM domains in ataxin-3. A new model was designed to fit the 
binding curves and accomodate for a three-site binding mechanism, under the assumption 
that all the binding sites have equal affinities to the UbLD. The resulting KD was 
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calculated to be 669±62 µM and 725±43 µM in the proton and nitrogen dimension, 
respectively (Figure 2.14).  
 
2.4 Discussion 
1H-15N HSQC titration experiments were used to determine the binding site of the 
ataxin-3 UIM123194-361 protein construct on the UbLD. To ensure that the chemical shift 
perturbations were due to protein interactions and not residues that are susceptible to pH 
changes, imidazole was added as a pH indicator to all of the NMR samples. Confidence 
in the reliability of the data can be based on four observable traits in the HSQC spectra; 
linear peak shifting, no systematic peak shifting is occurring, the peak shifts of different 
residues are in different directions, and the center of each peak is easily measurable and 
able to be followed (Figures 2.9, 2.12).  
2.4.1 The UIM regions of ataxin-3 interacts with the hydrophobic patch of the UbLD 
1H-15N HSQC titration experiments of 15N UbLD with up to a 6 equivalent 
addition of ataxin-3 UIM123194-361 revealed that most of the interacting residues reside on 
the solvent exposed surface of the beta-grasp fold of the UbLD, highlighted in pink 
(Figure 2.5). This region of interaction is similar to the interaction shown between the 
ataxin-3 UIM123194-361 bound to ubiquitin molecules (7). Like the UbLD interaction, the 
UIM region confers a docking site on the hydrophobic patch of Ub, centered on Leu8, 
Ile44, Lys48 and Val70 (7). When comparing the chemical shift perturbation map of 15N Ub 
vs. 15N UbLD  
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Figure 2.14 Binding curves of proton and nitrogen changes in chemical shift 
of 15N UbLD with titrations of ataxin-3194-361. The KD values are 668.7±61.70 
µM and 724.8±42.66 µM in the proton and nitrogen dimension, respectively. The 
fitting is based on a multisite non-linear regression analysis for 3:1 binding, with 
three equivalent affinity sites. The corresponding amino acid residues of which 
the chemical shifts were measured are indicated to the right side of the binding 
curve. 
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upon ataxin-3 binding, plotting the magnitude of chemical shift as a function of the 
residue position, the overall trends in which residues shift the greatest are almost identical 
(for example positions 8-13, 46-49, and residues at the C-terminus of both proteins) (7). 
The binding site on the UbLD and Ub is complementary to the UIM region of ataxin-3, 
which is composed of an acidic stretch of 3-4 residues followed by a hydrophobic core of 
typically 5 amino acid residues. Based on affinity binding assays the third UIM was 
found to not participate in the interaction to Ub and the KD of the Ub to ataxin-3 
UIM12194-261 interaction is just below 100 µM, which is relatively tight binding in the 
scope of UIM to UbLD binding interactions (7). The interaction between ataxin-3 and Ub 
is important for surveillance of its substrate proteins. Since ataxin-3 is a DUB enzyme, it 
is able to edit ubiquitin chains, preferably Lys63 Ub linkages important in DNA repair 
pathways, or specific substrates that require its surveillance (8). The biological 
importance of the interaction between ataxin-3 and the parkin UbLD is not well 
estabilished. Recently, ataxin-3 has been found to divert E2-Ub from parkin 
ubiquitylation by forming a stable complex between the E2, parkin, and ataxin-3, causing 
the ataxin-3 protein to become ubiquitylated (9). This is not the conventional de-
ubiquitylating mechanism, and ataxin-3 was originally thought to detach distal Ub 
moieties from a Ub-chain, though it is interesting that this mechanism is specific to 
parkin and could potentially rely on the UIM UbLD interaction (9). Despite the 
differences of biological importance in the interactions between Ub or UbLD to the UIMs 
of ataxin-3, the same hydrophobic and basic face of the Ub or UbLD is utilized to contact 
the UIM region. 
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2.4.2 Parkin UbLD makes weak and direct interactions with the three UIM regions of 
ataxin-3 
The arrangement of UIM sites within ataxin-3 are unique because no other UIM-
containing protein has three motifs in the same topology as ataxin-3, which are all located 
within the flexible C-terminal tail (10). A variable poly-glutamine tract separates the 
second and third UIM, that when expanded to greater than 45 residues, causes the most 
common dominantly inherited spinocerebellar ataxia. Meanwhile, UIM regions 1 and 2 
are much closer with one another in the protein sequence. The ataxin-3194-361 protein 
bound to the UbLD with a KD of ~230 µM, when the binding curves were globally fit 
with a 1:1 non-linear regression curve (Figure 2.13). This relatively weak interaction was 
expected, considering that other UIM-containing proteins such as Eps15 and S5a both 
bind to the UbLD with KDs in the range of 100-200 µM (2). With the interaction of 
ataxin-3 with UbLD proteins being transient in nature, these weak KD values are 
biologically significant.  
 
2.4.3 All three UIM regions of ataxin-3 participate in the interaction with parkin 
The most compelling results to show that all three UIMs are participating in the 
interaction to the UbLD were the NMR titrations of 15N ataxin-3 UIM123194-361 with 
UbLD additions and the reverse experiments of 15N UbLD with individually intact UIM 
regions. Previous evidence has shown that the conserved serine, which is present amongst 
all UIM sequences, is absolutely essential for the interaction with the UbLD and Ub (1, 
12).  To ensure that the UIM region has been ‘knocked down’ in its ability to interact to 
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the UbLD, we substituted five core hydrophobic residues to alanine residues to abolish 
interaction with the hydrophobic patch of the UbLD, and for preservation of the helical 
nature of the UIMs (2). Alanine substitutions of two conserved regions, the serine and 
five residue hydrophobic core both within the UIM sequence, provide confidence that the 
interaction between the UIM and UbLD is abolished. 
 NMR titration experiments of 15N UbLD with the C-terminal deletion ataxin-3 
construct of UIM1194-244, as well as the titration experiments with ataxin-3 UIM1*194-361 
provide evidence that supports that UIM1 is able to weakly bind to the UbLD (Figures 
2.11, 2.12C). The binding affinity was in agreement for both titration experiments with a 
KD value in the millimolar range. The observation that the binding affinities are in 
agreement, provides confidence that the alanine substitutions of the conserved serine and 
hydrophobic core of the UIM has lost its ability to interact with the UbLD.  
 Based on the NMR titration experiments of 15N UbLD with ataxin-3 UIM2*194-361, 
the second UIM has the tightest affinity to the UbLD compared with ataxin-3 UIM1*194-
361 and ataxin-3 UIM3*194-361 (Figure 2.10). It is not clear why the second UIM has the 
tightest binding affinity. Interestingly, previous evidence has shown that the opposite 
trend occurs for interaction with a single ubiquitin moiety. The ataxin-3 UIM1 binds 
tighter (KD = 215 µM) than UIM2 (KD = 309 µM), and UIM3 has the weakest affinity 
(KD > 3000 µM) (7). The explanation for why one UIM has a higher preference to bind 
the UbLD versus Ub or vice versa needs further investigation, however, in the scope of 
binding affinities, these are all within the same relatively weak binding range. 
The NMR titration experiments of the 15N UbLD with ataxin-3 UIM3*194-361 
additions, as well as the complementary experiment with 15N ataxin-3 UIM123194-361 both 
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provide compelling evidence to support that the third UIM is participating in the 
interaction. The 1H-15N HSQC spectra of 15N ataxin-3 UIM123194-361 was difficult to 
analyze due the overlap of peaks found in the proton dimension (7.7-8.8 ppm) which is 
indicative of a random coil protein (13). Some of the residues that are nearby or within 
the third UIM, S335, V344, and T345, could be tracked in the 1H-15N HSQC spectrum, 
and showed clear chemical shift perturbation upon additions of up to 10 equivalents of 
the UbLD (Figure 2.7). These same conserved residues are present within the third UIM, 
so one may predict that it is also involved in the interaction based on sequence identity to 
the N-terminal UIM regions. However, UIM interactions cannot be predicted based 
solely on sequence similarity as seen for UIM containing protein S5a which only utilizes 
its N-terminal UIM for interactions with parkin (1, 2).  
 
2.4.4 Differential interactions of the parkin UbLD with UIM-containing proteins 
Eps15, S5a and ataxin-3 
In 2001, there were approximately 30 reported proteins containing the ubiquitin 
interacting motif, and most of them contained more than one UIM (10). Since all UIMs 
have conserved elements within their ~20 amino acid motif, there is likely a lot of 
overlap in terms of which UIMs are able to bind to the UbLDs. The question then 
becomes, how can the parkin UbLD recognize which protein it is interacting with if many 
of its binding partners have UIMs? Two of the thirty identified UIM-containing proteins, 
Eps15 and S5a, have been extensively studied for their differential interaction with the 
parkin UbLD (2). K48, A46, and I66 are the hydrophobic residues on parkin that are 
occupied by the UIM(s) of Eps15, S5a and ataxin-3. Residues V56 and V15 in parkin 
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display large absolute chemical shift changes when ataxin-3 is added, whereas, in both 
Eps15 and S5a’s docking site, these two particular residues do not display a peak shift 
above the average shift (Figure 2.4) (2). Although, Eps15, S5a and ataxin-3 all contain 
more than one UIM in the C-terminal tail of their respective full-length proteins, the 
Eps15, S5a and ataxin-3 proteins behave very differently in their binding mechanisms to 
the UbLD. 
Eps15 utilizes two UIM regions to bind to the UbLD of parkin, meanwhile, S5a 
only uses one UIM and there is a clear distinction that the amount of surface area that is 
able to bind one UIM is less (9). Simply due to the number of surface residues displaying 
large chemical shifts upon addition of the ataxin-3 UIM123194-361, there seems to be a 
surface area that can accommodate one or two UIM regions simultaneously, but not three 
simultaneously. Further investigation of the binding between the proteins suggests that 
the third UIM is not a bystander in the interaction with parkin. The work presented here 
has shown that although the ataxin-3 UIM123194-361 confers a docking site that is in the 
same region where other UIM-containing proteins, such as Eps15 and S5a, bind to the 
parkin UbLD, the mechanism of interaction for ataxin-3 may be unique compared to 
Eps15 and S5a. 
 
2.4.5 The UIM region of ataxin-3 employs a multivalent binding mechanism to interact 
with the UbLD 
The multivalent binding mechanism is characterized by multiple weak binding 
sites that have fast off-rates, such that when the number of binding moieties increases, the 
affinity of binding becomes tighter (16). There are many pieces of evidence to suggest 
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that a multivalent binding interaction could be employed by the UIM region of ataxin-
3, one of which were the initial KD calculations between parkin and ataxin-3, which were 
carried out with a simple 1:1 binding model, referred to as the macroscopic dissociation 
constant. The preliminary analysis, from the ataxin-3 C-terminal deletion titration 
experiments, showed that increasing the number of UIM regions also increases the 
binding affinity to parkin. There was a tenfold increase in having the three UIM regions 
present versus one (Figure 2.13). Rap80, a DNA repair protein reported to use 
multivalent binding mechanisms to interact with ubiquitin chains, was found to have an 
increased affinity with increasing poly-ubiquitin chain length (16). Interestingly, Rap80 
has two tandem UIM regions and the discovery of how it binds to ubiquitin chains, 
preferentially Lys63 Ub linkages, was through 1H-15N NMR titration experiments as well 
as molecular dynamic simulations.   
 After close inspection of the data collected from the 1H-15N HSQC titration 
experiments with the UbLD and various UIM constructs, a new multivalent binding 
equation was derived. The model assumes that only a single UbLD can bind to a single 
UIM site at one time point with equal binding affinities, which was validated from 
considering the chance that two UbLD moieties could simultaneous bind was very 
unlikely, that the affinities of each UIM interacting with the UbLD were similarily weak, 
and that the docking site on the UbLD could accommodate one to two UIM sites. The 
KDs derived from the multivalent 3:1 binding model were 668.7±62 µM and 724.8±43 
µM in the proton and nitrogen dimension, respectively. Importantly, these KD values 
were similar to the KD values derived from the experiments involving ataxin-3 UIM1*194-
361, UIM2*194-361, and UIM3*194-361, which were 840.3±188.6 µM, 502.3±41.4 µM, and 
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921.0±165.0 µM, respectively (Figure 2.11). The similarity between the two derived 
KD values, fit with the appropriate 1:1 or multivalent 3:1 binding model, provides support 
that the multivalent type of fit is appropriate for the chemical shift perturbation data when 
the ataxin-3 UIM123194-361 construct is titrated into 15N UbLD.  
 
2.4.6 Biological importance of the DUB enzyme and E3 ligase interaction 
In 2010, the Fon group proposed that self-ubiquitinating E3 ligases have a 
‘relationship’ with DUB enzyme(s) to prevent their own rapid turnover via the 
proteasome. This has been seen for other E3:DUB pairs, such as MDM2:HAUSP, and 
ITCH:FAM/USP9X (1,14). Recently, there has been evidence to supporting the 
importance of the interaction of parkin and ataxin-3. Interestingly, ataxin-3 can be 
ubiquitylated, preferentially at Lys117, which enhances its DUB catalytic activity in vitro 
and in cells (15). Ataxin-3 was shown to preferentially deubiquitinate FLAG-parkin 
ubiquitin chains versus free ubiquitin chains or ubiquitin chains on other RING E3 
ligases such as SIAH and CIAP2 (1). As well, there is evidence to show that ataxin-3 has 
a unique mechanism to prevent parkin from being ubiquitylated by sequestering an E2 
(Ubc7) in complex with parkin and diverting the Ub moiety onto ataxin-3 itself (9). This 
suggests that there is specificity in the DUB function of ataxin-3 for parkin. In addition, 
cyclohexamide pulse-chase experiments, when the ataxin-3 polyglutamine tract is at a 
disease relevant length (82Qs), causes parkin levels to drop in the cell due to increased 
turnover by autophagy (1). All of these examples provide growing evidence to support 
that ataxin-3 has a ‘partnership’ with parkin for interplay in regulating each other’s 
function.   
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In this work, NMR titration experiments were used to identify the binding site 
that the UIMs of ataxin-3 confer on parkin UbLD, as well as, investigate the binding 
mechanism and importance of the third C-terminal UIM. In identifying the site of 
interaction on the UbLD, prediction of ARJP mutations that may be relevant for 
disrupting the interaction to ataxin-3 is possible. Further, this work provides evidence that 
the binding interface on parkin where the three UIMs of ataxin-3 interacts, lies on the 
hydrophobic patch of parkin but provides unique contacts that have not been present in 
Eps15 or S5a UIM to UbLD protein interactions (2). Individually, each UIM has a very 
weak affinity for the UbLD, in the one millimolar range. The binding affinity is the 
greatest when all three UIMs are intact and are available to interact with the UbLD. 
Collectively, the results led to the prediction that there may be a multivalent binding 
mechanism between the UIM region of ataxin-3 and the parkin UbLD.  
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Chapter 3  
STRUCTURALLY INTACT DISEASE STATE MUTATIONS WITHIN PARKIN 
UBLD RETAIN INTERACTION WITH THE ATAXIN-3 UIM REGION 
 
3.1 Introduction 
Greater than 50% of Autosomal Recessive Juvenile Parkinsonism (ARJP) patients 
have mutations attributed to the parkin gene (1). In the parkin Ubiquitin-Like Domain 
(UbLD) alone, there have been 20 ARJP substitutions identified in 16 different amino 
acid residue positions (2). This chapter provides analysis on a selection of these ARJP 
single amino acid substitutions within the UbLD and interaction studies with ataxin-3. 
Certain ARJP substitutions on the UbLD can compromise the interaction with the UIM 
regions, as seen previously, with the UIM-containing protein S5a, which is a component 
of the 19S regulatory subunit involved in proteasomal degradation (1). The loss of the 
parkin-S5a interaction is proposed to result in impaired delivery of parkin ubiquitylated 
substrates to the proteasome. This could be a source of pathogenesis to seed protein 
misfolding diseases. This work aimed to determine what effect certain ARJP substitutions 
would have on the interaction of the UbLD with the UIM containing region of ataxin-3. 
However, the biological outcome of the disruption of the parkin UbLD interaction with 
ataxin-3 is unknown. Currently, binding assays provide evidence to suggest that the 
interaction between ataxin-3 and parkin is bimodal, with a second interaction site located 
in the Josephin domain of ataxin-3 to the IBR-RING2 of parkin (3). It may be possible 
that if the interaction between an ARJP mutant containing UbLD and ataxin-3 UIM 
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region is compromised, the interaction between parkin and ataxin-3 may still exist 
through the 2nd interaction site, the parkin IBR-RING2 and the Josephin domain. 
The following ARJP substitutions were selected for study, UbLDV15M (4), 
UbLDR33Q (5), UbLDA46P (6), and UbLDK48A (7). The ARJP substitutions were selected 
because they have minimal affect on the three dimensional structure of the UbLD based 
on extensive structural characterization by NMR spectroscopy and circular dichroism 
spectropolarimetry (2). The only exception is UbLDA46P, which has been previously 
shown to be unfolded (4). Secondly, these ARJP substitutions have been shown to 
participate in the interaction or are nearby the interaction site between the UIM region of 
ataxin-3 and the UbLD. Understanding the underlying mechanisms for the wildtype 
interaction of parkin and ataxin-3, discussed in Chapter 2, are highlighted here by 
showing how these disease relevant substitutions on parkin may compromise the 
interaction to the UIM regions. 
In this work, the aim was to investigate ARJP substituted UbLD proteins that are 
structurally unaffected, to determine whether these mutations specifically alter the 
interaction with ataxin-3. To address this objective the structures of several ARJP 
substituted UbLD proteins (UbLDV15M and UbLDK48A) were assessed by NMR 1H-15N 
HSQC titration experiments, and the interaction between ataxin-3 UIM123194-361 and 
substituted UbLD proteins were investigated by an affinity binding assay and NMR 
titrations. Lastly, the binding affinities were quantified by NMR titrations. 
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3.2 Materials and Methods 
3.2.1 Parkin ARJP substitutions within the UbLD 
 Parkin UbLD molecular biology details are described in Chapter 2. The ARJP 
relevant mutants used for the interaction studies (V15M, R33Q, A46P, K48A) were 
generated previously through using QuikChange Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA) (2). All constructs were expressed without fusion tags. The 
mutant parkin UbLD constructs were verified by DNA sequencing (Robarts Sequencing 
Facility). 
 
3.2.2 Expression and purification of parkin ARJP substituted proteins  
ARJP substituted UbLD constructs were overexpressed and purified as described 
for the wildtype human parkin UbLD, described in Chapter 2. The integrity of all proteins 
were confirmed by electrospray ionization mass spectrometry (2).  
 
3.2.3 Expression and purification of ubiquitin 
Human ubiquitin was overexpressed in the pLysS Escherichia coli strain. The 
bacterial culture was grown as described for the parkin UbLD, with the exception that 
induction of expression with the addition of 1 mM IPTG at an A600 of 0.4-0.5. Both the 
overnight culture and the large growths of bacteria were grown in Luria-Bertani media 
and contained ampicillin (50 µg/ml) and chloramphenicol (34 µg/ml). Cell lysis was 
completed using flash freezing with liquid nitrogen and thawing, followed by sonication. 
The cell homogenate was then spun at 132380 g for 60 minutes, the supernatant was 
slowly brought to a pH of 3.5 and spun at 7378g. The supernatant was extensively 
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dialyzed with 25 mM Tris, 1 mM EDTA, and 150 mM NaCl at pH 8, loaded onto a 
G75 sizing column and eluted as described previously for parkin UbLD, Chapter 2.  
 
3.2.4 ARJP substituted parkin UbLD binding assay with His-tagged ataxin-3 
UIM123194-361   
All pure protein samples were extensively dialyzed in binding buffer (20 mM 
sodium phosphate, 10 mM imidazole, 300 mM NaCl, pH 8) prior to mixing the proteins. 
Purified His-tagged ataxin-3 UIM123194-361 proteins were placed in an eppendorf tube on 
a rotating mixer and incubated with either parkin UbLD, ARJP substitutions of the parkin 
UbLD (K48A, A46P, R33Q, V15M), or ubiquitin, to give a final volume of 300 µL, at 
4°C for one hour. Mixtures of 1:2 molar ratio His-tagged ataxin-3 construct:UbLD, (or 
ubiquitin) were used; concentrations were determined by the BIO-RAD protein assay. 
The principal behind this assay involves using the acidic Coomassie Brilliant Blue G-250 
dye that changes color upon binding to protein, which can then be measured at an 
absorbance of 595 nm by a spectrophotometer. Beer’s law is then applied to quantitate 
the protein concentrations. Following incubation of the protein mixture, a total volume of 
300 µL was loaded on a Ni-NTA spin column (Qiagen) and incubated for 3 minutes at 
room temperature before being spun at 6 g. The column was washed twice with 600 µL 
of binding buffer and eluted with the same buffer, but with 250 mM imidazole. Eluted 
samples were separated by electrophoresis on a 16.5% tris-tricine polyacrylamide gel and 
stained with Coomassie brilliant blue dye.   
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3.2.5 NMR spectroscopy titration experiments  
The 1H-15N Heteronuclear Single Quantum Coherence (HSQC) NMR 
experiments were performed with a 600 MHz Varian Inova spectrometer (BioNMR 
Facility, UWO). All protein samples were extensively dialyzed into 11 mM KH2PO4, 150 
mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, at pH 7 and 100 µM imidazole was added 
in the final NMR sample to serve as a pH indicator. All spectra were recorded at 25°C. 
Prism 4 and NMRViewJ version 8.0.rc4 were used to fit non-linear regression and global 
fitting for a 3:1 multivalent binding model, derived from following chemical shift 
perturbations upon titrating an unlabeled binding partner into the 15N-labeled protein 
species. Details about the equation used for the multivalent binding fit is included in the 
Materials and Methods section of Chapter 2.  
 
3.3 Results 
 ARJP-substituted UbLD proteins had similar yields of pure protein per litre of 
bacterial growth compared to wildtype (WT) UbLD (approximately 10 mg), with the 
exception of UbLDA46P which has approximately half the UbLDWT yield (~5 mg). The 
purification protocol used for WT UbLD was also successful for purifying the ARJP-
substituted proteins, UbLDV15M, UbLDR33Q, UbLDA46P and UbLDK48A. This suggests that 
the size and shape of all the UbLD proteins are alike and soluble, with the exception of 
UbLDA46P, which may be prone to degradation, shown previously, or in the insoluble 
fraction (2). Following purification, affinity binding assays and NMR titration 
experiments were utilized to investigate whether structurally intact ARJP-substituted 
UbLD proteins were able to sustain the interaction with the UIM region of ataxin-3.  
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3.3.1 K48A and V15M ARJP substitutions in the UbLD retain their domain structure 
1H-15N HSQC experiments were used to determine whether any local or global 
changes in structure occur, upon the ARJP substitutions UbLDV15M and UbLDK48A. 
Comparisons of the spectra between the UbLDK48A and the UbLDWT showed no drastic 
differences in spectral dispersion, as >80% of the resonances overlaid with the WT UbLD 
resonance positions (Figure 3.1). The 1H-15N HSQC spectra of the UbLDV15M had less 
overlap with the WT UbLD. Approximately 60% of the resonances overlaid with their 
locations on the original WT UbLD 1H-15N HSQC, and the broad spectral dispersion in 
the proton dimension was maintained (Figure 3.1). When comparing the UbLDK48A 1H-
15N HSQC spectrum with the WT UbLD spectrum, there were approximately 5 peaks that 
show a greater difference in resonance position compared to others including Leu26, 
Gln64, Leu61, Trp74, and Arg75. These residues do not reside in the same region of the 
UbLD. Leu61 is the closest in space with the Lys48 position. The remaining residues are 
located much farther in 3D space to the Lys48 position. For example, Gln64 is located at 
the N-terminus of the β5 strand, Trp74 and Arg75 are both located on the flexible C-
terminal tail and Leu26 is on the α2 helix and has its side chain pointing towards the 
inside of the beta grasp fold. The resonances that change upon substitution of V15M are 
different than those seen in the K48A substituted UbLD. For example Leu61 changes its 
resonance for both ARJP substitutions but the resonance was more upfield in the 
UbLDK48A spectrum, meanwhile the Leu61 peak in UbLDV15M shifted more downfield 
(Figure 3.1). Despite all the resonances that are altered upon a single amino acid 
substitution, the peaks still remain well dispersed in the proton-dimension, and overlay  
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Figure 3.1. 1H-15N HSQC spectra of wildtype (black) UbLD overlaid with 
ARJP substituted UbLDK48A (blue) and UbLDV15M (red). The spectra were 
collected on a Varian INOVA 600 MHz NMR spectrometer with samples in a 
buffer containing 10 mM KH2PO4, 1 mM EDTA, 1 mM DTT pH 7.0 at 25°C (pH 
indicator, Imidazole). The concentration of 15N labeled parkin wildtype UbLD 
and ARJP substituted UbLDK48A samples were 100 µM, while the UbLDV15M 
sample was 150 µM. The ribbon diagram of the UbLD highlights the position of 
the substitution depicted with the original side chain colored blue (K48) and red 
(V15). 
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well with the WT spectrum. Overall, the chemical shift changes are small (<0.1ppm in 
the proton dimension, and <2.0ppm in the nitrogen dimension) (Figure 3.1). This 
suggests that the general domain fold was intact and similar to the UbLDWT, and only 
local changes occurred after the introduction of the V15M and K48A substitutions. 
3.3.2 Structurally intact ARJP substituted UbLD proteins can interact with ataxin-3 
UIM123194-361  
 An affinity-binding assay was used to assess whether ARJP substitutions within 
the UbLD can interact with ataxin-3 UIM123194-361. The ataxin-3 UIM123194-361 construct 
contains a His-tag and was incubated with one of the UbLD proteins. After washing the 
nickel column with the pre-loaded incubated protein samples, gel electrophoresis was 
used to detect the presence the ARJP-mutant UbLD proteins from the eluted samples 
(Figure 3.2). UbLDA46P and the UbLDWT were used as negative and positive controls in 
the binding assay. The first three lanes in the gel show the Ni-NTA spin column elution 
of His-tagged ataxin-3 UIM123194-361, UbLD, and Ub proteins alone. The elution fraction 
of the mixtures of His-tagged ataxin-3 UIM123194-361 with Ub, UbLD, UbLDV15M, 
UbLDR33Q, UbLDA46P and UbLDK48A are shown (Figure 3.2). The intensity of the WT 
UbLD elution band was similar in intensity with UbLDV15M, UbLDR33Q, and UbLDK48A 
for the mixtures with His-tagged ataxin-3 UIM123194-361. Loading amounts were the same 
amongst the WT UbLD and UbLD variants (Figure 3.2). The elution of the UbLDA46P 
and Ub band are fainter, indicating poorer binding. The His-tagged ataxin-3 UIM123194-
361, indicated by a yellow arrow, has a similar protein band intensity at the same position 
in the polyacrylamide gel to one another, just above 25 kDa (Figure 3.2).  
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Figure 3.2. Affinity binding assay of the his-tagged ataxin-3 UIM123194-361 and 
ARJP disease substitutions, UbLDV15M, UbLDR33Q, UbLDA46P, UbLDK48A, 
wildtype UbLD and ubiquitin. The top panel is an SDS-PAGE showing the 
elution of the Ni-NTA column for His-tagged ataxin-3 UIM123194-361 and various 
UbLD species for an hour at room temperature. Mixtures of his-tagged ataxin-3 
and UbLD, or ubiquitin in 1:2 molar ratios were used. Two washing steps were 
carried out prior to the elution step. The yellow arrow is indicating the his-tagged 
ataxin-3 UIMs protein band. The protein bands that are just below 10 kDa are the 
non-tagged eluted UbLD or Ub species. The bottom panel is an SDS-PAGE of the 
purified UbLD species from a 200 µM stock that was used in the binding assay. 
The (+), indicates the positive control in the binding assay. 
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 The NMR titration experiments with 15N-labeled UbLDK48A and UbLDV15M 
showed that specific residues experience different chemical shift changes upon titration 
with ataxin-3 UIM123194-361. Residues Phe13, Leu61, Gln64 and Ile66 all experience 
changes in chemical shift in both similar magnitude and direction in both UbLDK48A and 
UbLDV15M proteins (Figures 3.3, 3.4). In the titration experiment involving UbLDV15M, 
Lys48 showed the largest chemical shift change in response to ataxin-3 UIM titrations. 
The titration experiments involving 15N UbLDK48A, the resonance corresponding to Val15 
also experiences a change in chemical shift (Figure 3.4). The V15M substitution resulted 
in the methionine resonance to experience very minimal chemical shift perturbations, 
originally shifting >0.5 ppm (Val15) in the nitrogen dimension to <0.2 ppm (Met15) 
(Figure 3.3). The resulting substituted Ala48 could not be identified on the HSQC spectra, 
as the backbone assignments for the UbLDK48A had not been completed. These results 
suggest that both the Val15 and Lys48 positions are participating in the interaction with 
ataxin-3 UIM region and the substitution of these residues has the potential to 
compromise the interaction to ataxin-3.  
  
3.3.3 K48A and V15M ARJP substituted UbLD proteins utilize the same binding 
surface on the UbLD to interact with the UIMs of ataxin-3 
Multiple resonances from the 1H-15N HSQC spectra of UbLDK48A and UbLDV15M 
exhibit similar chemical shift perturbation behavior upon ataxin-3 additions. As 
mentioned above, residues Ile66, Phe13, Leu61, and Gln64 all experience similar resonance 
movement in both titration experiments (Figures 3.3, 3.4, 3.5). These are also the  
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  Figure 3.3 Select region of the 1H-15N HSQC spectra of 15N-labeled parkin 
UbLDK48A (A) and UbLDV15M (B) overlaid following incremental additions 
of ataxin-3 UIM123194-361. The starting concentration of 15N labeled parkin 
UbLDK48A was 100 µM and UbLDV15M was 150 µM. The ARJP substituted 
UbLD were titrated with up to four (A), and five (B) equivalents of unlabeled 
ataxin-3 UIM123194-361, respectively. Resonances that exhibit similar behavior 
(Phe13, Ile66 and Gln64) are highlighted (red) for both titration experiments. 
Peaks are shifting from light colored to dark colored. 
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Figure 3.4 Regions of 1H-15N HSQC spectra of 15N parkin UbLDK48A (A, B, 
C) and UbLDV15M (D, E, F) overlaid with HSQC spectra of incremental 
additions of ataxin-3 UIM123194-361. NMR data was collected on a Varian 
INOVA 600 MHz NMR spectrometer with samples in a buffer containing 10 
mM KH2PO4, 1 mM EDTA, 1 mM DTT pH 7.0 at 25°C (pH indicator, 
Imidazole). The starting concentration of 15N labeled parkin UbLDK48A was 100 
µM and UbLDV15M was 150 µM. The ARJP substituted UbLD was titrated with 
up to four (A, B, C), and five (D, E, F) equivalents of unlabeled ataxin-3 
UIM123194-361, respectively. This figure highlights the similar peak shifting 
behavior for amino acid residues Leu61 and Gln64 for both titration experiments. 
The V15 and K48 peak shifts are highlighted in the parkin UbLDK48A and parkin 
UbLDV15M spectra, respectively. 
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Figure 3.5 Chemical shift perturbation data and corresponding surface 
representation of the wildtype parkin UbLD (A), UbLDV15M (B), and UbLDK48A 
(C) upon ataxin-3 UIM123194-361 binding. Chemical shift perturbation maps of the 
UbLD by measuring the absolute magnitude of peak shifting that occurs after addition of 6 
eq.,5eq., and 4eq. of ataxin-3, respectively. The dotted lines indicate 0.5 S.D. above the 
average chemical shift perturbation value. The surface representations of where the three 
UIM containing region of ataxin-3 UIM123194-361 confer their binding spot on the wildtype 
UbLD (A), UbLDV15M (B), and UbLDK48A (C). The residues that displayed more than 0.5 
standard deviation above the average chemical shift were mapped on the surface of the UbLD, 
which is highlighted in pink (wildtype UbLD), green (UbLDV15M) and orange (UbLDK48A). 
The surface representations were created in the program PyMOL all using the PDB code 
1IYF, structure of the wildtype human parkin UbLD. 
 
   82
  
resonances that experienced some of the greatest chemical shift perturbations upon 
titrations of ataxin-3 UIM123194-361 (Figures 3.3, 3.4). The interaction surface is similar 
for ARJP substituted proteins UbLDV15M and UbLDK48A initially based on the 
observations that multiple similar residues display chemical shift changes for both NMR 
titration experiments. After further investigation, by using chemical shift perturbation 
data and mapping the residues on the UbLD for chemical shift changes greater than 0.5 
S.D. above the average chemical shift, it is clear that the surface of the beta-grasp fold is 
utilized for ataxin-3 binding in both cases (Figure 3.5). The chemical shift perturbation 
data show that upon substitution of a particular residue, the nearby residues that once 
displayed a large absolute chemical shift difference upon addition of ataxin-3, greater 
than 0.5 S.D. above the average chemical shift (dotted line), now display a much smaller 
absolute change in chemical shift which is below the dotted line (Figure 3.5). An example 
of this is the K48A substitution, because in the original wildtype interaction, residues 
Lys48, Glu49, Ala46 all contribute to the binding surface for the UIM region of ataxin-3. 
However, once Lys48 is substituted to an alanine, those nearby residues do not experience 
a great chemical shift perturbation anymore (Figure 3.5C). The same occurs for the 
UbLDV15M substitution. Nevertheless, even though these small differences occur, the 
UbLDV15M and UbLDK48A utilize a similar binding surface to interact with ataxin-3 
UIM123194-361 compared to each other and compared to the wildtype UbLD. 
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3.3.4 Structurally unaffected ARJP-substituted UbLD proteins interact with ataxin-3 
with a similar binding affinity 
 The data from the NMR titration experiments (Figure 3.3) was used to calculate 
the affinities between the UbLD proteins, (UbLDK48A and UbLDV15M) and the ataxin-3 
UIM123194-361. This analysis revealed that the affinities are very similar. Chemical shift 
changes for five residues, Phe13, Val43, Leu61, Gln64 and Arg75, from the 1H-15N HSQC of 
UbLDK48A spectra were plotted as a function of ataxin-3 UIM123194-361 additions (Figure 
3.6). The resonances followed for the 1H-15N HSQC of UbLDV15M belonged to residues, 
Phe13, Leu61, Gln64, Ser65, Val67, and also plotted as a function of ataxin-3 UIM123194-361 
additions. The calculated dissociation constant for UbLDK48A was 658.9±48 µM and for 
UbLDV15M was 700.4±102 µM. These dissociation constants were calculated based on a 
global fit for a three-site multivalent binding model with equal binding affinities (Figure 
3.6). These dissociation constants were very similar to that calculated for WT UbLD 
binding to ataxin-3, Chapter 2. These observations show the ARJP substitutions do not 
abolish the binding between the UbLD and ataxin-3. 
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Figure 3.6 Binding curves of the absolute change in chemical shift of 15N 
UbLDK48A and UbLDV15M with titrations of ataxin-3 UIM123194-361. The 
absolute chemical shifts are taken into consideration, both the proton and 
nitrogen chemical shifts (in ppm). The KD values are KD, UbLDK48A = 
658.9±47.79 µM and KD, UbLDV15M = 700.4±102.7 µM and were based on a 
global fit for a three equivalent multisite binding model. The starting 
concentration of the ARJP substituted 15N UbLDK48A and UbLDV15M were 100 
µM and 150 µM, respectively.  
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3.4 Discussion 
 In this work the interactions between the ARJP substituted UbLD proteins and 
three UIM regions of ataxin-3 were investigated mostly by the 1H-15N HSQC spectra 
during titration experiments and the affinity-tag binding assays. Results show that the 
structurally intact ARJP substitutions retain the interaction with the ataxin-3 UIMs. As 
well, for the first time, dissociation constants were calculated for these interactions 
between the UbLDV15M, UbLDK48A and ataxin-3194-361 and were found to have very 
similar to the KD determined for the wildtype UbLD interaction. It should be noted that 
the pathogenic link to ARJP UbLDK48A remains unclear although it has been reposted in 
the literature (7). Protein characterization studies continue to study UbLDK48A, due to the 
importance of the residue for interactions. Although this mutation has been reported, it 
does not appear in Parkinson’s disease databases (2, 7, 
http://www.molgen.ua.ac.be/PDmutDB). 
 
3.4.1 1H-15N HSQC experiments show that UbLDV15M and UbLDK48A are structurally 
intact  
The dispersion of resonances in the proton dimension and the significant overlap 
of resonances in the 1H-15N HSQC spectra between ARJP substituted UbLD proteins and 
WT UbLD confirm that the protein domains remain well-folded with only local structural 
changes. The UbLDK48A 1H-15N HSQC spectrum overlayed extremely well with that of 
the WT UbLD spectrum, indicating no gross structural changes had occurred (Figure 
3.1). Approximately half of the resonances that were different from the WT UbLD 
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belonged to residues that were present in flexible regions, such as the C-terminal tail. 
There were a greater number of differences in resonance positions between the 
UbLDV15M 1H-15N HSQC spectrum compared to that of the WT UbLD, but this would be 
expected due to the location of the Val15 position in the UbLD structure (Figure 3.1). 
Unlike Lys48 position on the UbLD, which is solvent exposed, the Val15 position resides 
on the β2 strand pointing towards the α2 helix. This suggests that the substitution of Val15 
could modify intramolecular Van der Waals and hydrophobic interactions that stabilize 
the fold of the protein such as that with Val29, which is located on the α2 helix and points 
towards the Val15 side chain. The V15M substitution may be altering the existing 
hydrophobic stabilizing interaction and this loss may change the chemical environment 
for many residues that rely on this stabilization. Despite the greater number of resonances 
that differ between the UbLDV15M 1H-15N HSQC spectrum and the UbLDWT spectrum 
compared to the UbLDK48A 1H-15N HSQC spectrum and the UbLDWT, the conclusion is 
that both UbLDV15M and UbLDK48A maintain the domain fold based on minimal changes 
in the proton dispersion in the spectra and thus, exposes the essential interacting residues 
in the hydrophobic patch to interact with the UIM region of ataxin-3. 
In addition to the NMR experiments that were carried out, the structural integrity 
of the V15M, R33Q, and K48A ARJP substitutions within the UbLD have been 
previously studied by circular dichroism spectropolarimetry and NMR 1H-15N HSQC 
experiments (2). The results are consistent with our findings by NMR spectroscopy. 
These ARJP mutants maintain the five-strand β-grasp fold, typical of the UbLD and Ub 
molecule, while A46P was completely unfolded (2). The 1H-15N HSQC spectra of 
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UbLDV15M and UbLDK48A were identical to the spectra of previous work done to 
characterize these two proteins (Figure 3.1) (2).  
 
3.4.2 The affinity binding assay shows that the interaction between the structurally 
unaffected disease-state UbLD proteins and UIMs of ataxin-3 are not disrupted 
The affinity-binding assay was used as further confirmation and completeness of 
determining if an ARJP substituted UbLD was able to disrupt the interaction to ataxin-3 
UIM123194-361.  The results showed that all proteins, WT UbLD, UbLDV15M, UbLDR33Q, 
and UbLDK48A were able to interact with the UIM region of ataxin-3 and with similar 
affinities (Figure 3.2). The UbLDA46P protein band appears more faint, suggesting that the 
interaction with ataxin-3 is much weaker than the WT UbLD, UbLDV15M, UbLDR33Q, and 
UbLDK48A (Figure 3.2). The ARJP substitution of a single amino acid, (V15M, K32T, 
R33Q, and P37L) has been previously shown to compromise the interaction between the 
UIM region of S5a (2). This led to the investigation of V15M, R33Q and K48A 
substitutions, on the basis that they are all structurally intact and also because of their 
close proximity to the binding interface of the UIM binding site on the UbLD. The 
UbLDA46P has been shown previously to be completely unfolded, by the loss of alpha 
helix and beta sheet signals in the CD spectra and by observing a collapse of peaks in the 
NMR HSQC experiments, which is an indication of protein unfolding (2). Thus, 
UbLDA46P was used as a negative control for the binding assay as the interaction surface 
where UIMs typically bind would be disrupted and should result in no binding. However, 
residual binding was detected for the UbLDA46P protein, possibly caused by nonspecific 
binding to the resin of the column used (Figure 3.2). Analysis of the affinity binding 
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assay alone provides a qualitative assessment that the structurally intact ARJP 
substituted UbLD proteins are able to bind to ataxin-3 with a similar affinity compared 
with UbLDWT. 
 
3.4.3 NMR titration interaction studies between UbLDV15M, UbLDK48A and ataxin-3 
The NMR titrations confirmed that the UbLDV15M and UbLDK48A utilize many 
identical residues to interact with ataxin-3 UIM123194-361. The observation that Ile66, 
Phe13, Leu61, and Gln64 participate in the interaction for both UbLDV15M and UbLDK48A 
was expected, because these are also the residues that display great chemical shifts in the 
NMR titrations of the wildtype interaction between the UbLD and UIMs as noted in 
Chapter 2. Even though both residues Lys48 and Val15 participate in the wildtype 
interaction, based on NMR titration experiments, the substitution of these residues does 
not disrupt the binding significantly. The dissociation constant for UbLDK48A and 
UbLDV15M were KD, UbLDK48A=658.9±47.79 µM and KD, UbLDV15M=700.4±102.7 µM for a 
three equivalent multisite binding model (Figure 3.5). These KD values are not 
significantly different from the wildtype KD which was 668.7±61.70 µM for a three 
equivalent multisite binding model (Chapter 2). An explanation for why these two 
particular structurally intact ARJP mutants did not drastically change the affinity of 
binding to the UIM region could be because both residues do not lie at the centre of the 
hydrophobic patch, which was found to be the ‘heart’ of the docking site for the ataxin-3 
UIM region. Lys48 lies at the edge of the hydrophobic patch, on the β4 strand, while Val15 
lies at the opposite edge of the hydrophobic patch with its side chain pointing away from 
the solvent exposed beta sheet. The proximity of these two ARJP substitutions were not 
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close to the center of the docking site for the UIMs and perhaps, are not important 
residues for the interaction with the UIM region of ataxin-3. In support of this, previous 
studies performed on ARJP substituted UbLD proteins and interactions with the UIM 
region of S5a showed that the structurally intact ARJP-substituted proteins which 
compromised the binding affinity to the S5a protein were residues that were interacting 
with a key residue, Phe13, for the wildtype interaction between UbLD and UIM (2). Many 
of the ARJP-substituted UbLD proteins also had decreased stability, based on thermal 
unfolding experiments, which may have altered the interaction site for the S5a (2). Some 
of the ARJP-substituted UbLD proteins that resulted in decreased domain stability were 
also used in the study with ataxin-3, such as UbLDV15M and UbLDR33Q, however, the 
decrease in stability does not effect the binding to ataxin-3. The structurally intact 
disease-state UbLD substitutions that were studied for interactions with ataxin-3 
(UbLDV15M, UbLDR33Q, and UbLDK48A), can all retain their interaction with ataxin-3. 
This suggests that these particular ARJP substitutions may have a larger impact on 
interactions to other proteins, such as S5a, or have an altered pathogenic pathway that 
does not involve ataxin-3. 
 
3.4.4 Alternate pathogenic pathways for ARJP-substituted UbLD proteins 
Many identified ARJP substitutions within the UbLD of parkin have been 
categorized in terms of how they could be contributing to pathogenic outcomes, such as 
completely unfolding the UbLD structure, disrupting important protein-protein 
interactions, or decreasing the stability of the domain structure and full-length parkin 
protein (2, 8, 9). There are also unidentified pathogenic outcomes for some ARJP 
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substitutions. Most recently, it has been proposed that the parkin UbLD has a role in 
autoinhibition of its catalytic ubiquitin ligase activity, more specifically in 
autoubiquitination (8). The N-terminal UbLD was found to interact with a ΔUbLD 
parkin77-465 construct. The Lys48 position, which is completely conserved in ubiquitin and 
acts as the site of polyubiquitin chain building for degradation signaling, had been shown 
to be an essential residue to support the autoinhibited state of parkin (8). When the Lys48 
was substituted with a non-charged residue alanine, as opposed to maintaining the same 
charge with a residue like arginine, the autoinhibition was compromised and it resulted in 
an increased autoubiquitination of parkin. This suggests that the electrostatic nature of the 
Lys48 is essential to the intramolecular autoinhibited state of parkin, and that the 
substitution of K48A could cause an increased turnover of parkin through the 
proteasomal degradation pathway (8). Walden’s group also tested the UbLDA46P and 
found that this ARJP substituted protein does disrupt the autoinhibition of parkin, 
suggesting that the UbLD structure must be intact to be able to expose the residues most 
important for interacting with a ΔUbLD parkin77-465 construct (8). 
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Chapter 4 
SUMMARY AND PERSPECTIVES 
 
4.1 Introduction 
The ubiquitin signaling pathway (USP) involves hundreds of enzymes and is 
utilized in multiple regulatory pathways, such as proteasomal degradation, endocytosis 
and DNA repair. Many protein misfolding neurodegenerative diseases have been linked 
to the USP, which has drawn attention to the investigation of the structure and function of 
enzymes involved in this multifaceted pathway. Conjugation of a Ub molecule or a poly-
Ub chain onto a target protein is a tightly regulated process and it is also reversible. An 
early-onset form of Parkinson’s disease (PD) has been linked with parkin, an E3 Ub 
ligase, which participates in the last step of conjugating the Ub moiety onto a specific 
target protein. Machado Joseph disease (MJD) is the most common dominantly inherited 
ataxia and has been linked with a poly-glutamine expansion in the ataxin-3 DUB enzyme, 
which has a role in detaching Ub moieties. Both MJD and PD are progressive diseases 
and patients of these diseases can present with a wide variety of clinical symptoms. 
Interestingly, the clinical presentations in MJD and PD can overlap, as it has been 
reported that MJD patients have parkinsonism like behaviour (1).    
4.2 Previous Work 
There is potential for neuropathological overlap between the two disease states, 
PD and MJD, since parkin and ataxin-3 are multi-domain proteins with an assemblage of 
ubiquitin-signaling relevant domains. Observations of overlapping clinical symptoms for 
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patients with Machado Joseph Disease (MJD) and patients with PD, such as tremors 
and muscle rigidity, supports the hypothesis (1). In addition, similar areas of the brain are 
negatively affected in MJD and PD, such as the substantia nigra; however, there are many 
areas of the brain that are divergently affected in the two disease states (3). Some of the 
patients with MJD that display parkinsonism characteristics, respond well to levodopa 
treatment (4). These two proteins have already been identified to be functionally 
interactive by their interplay between ubiquitylating and deubiquitinating one another to 
regulate the function of both proteins (2,5). All of the clinical observations and 
experimental evidence emphasizes the importance of the interaction between parkin and 
ataxin-3. Further investigation needs to be focused on how the disease-relevant 
mutations, on either parkin or ataxin-3, affect the neurobiology in affected areas in the 
brain.   
In 2010, parkin was reported to directly interact with ataxin-3, however details 
regarding the residues involved in the binding site, binding mechanism and affinity of 
binding were not elucidated (2). By performing multiple affinity binding assays, the 
group was able to narrow down the binding region to the C-terminal UIM region of 
ataxin-3 and the N-terminal UbLD of parkin (2). In Dr. Fon’s group, they found that 
GST-tagged parkin lacking the UbLD could still bind to full-length ataxin-3, which 
suggests that there is another interaction site. Further investigation led to the discovery 
that is was an interaction between the ataxin-3 N-terminal Josephin domain with the IBR-
RING2 of parkin (2). In this work, the focus was only on the UbLD and UIM constructs, 
but if this interaction is complicated by another site of binding, further investigation is 
needed to fully appreciate the biological binding mechanism between ataxin-3 and 
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parkin. It would be interesting to determine the binding affinity of this interaction 
through NMR titration experiments, however, the Josephin domain and IBR-RING2 
would form a much larger complex than the UIM region and UbLD. The large complex 
will slow the tumbling time in the protein sample and the peaks may be difficult to 
resolve due to the broadening of peaks. It is important to study the second potential 
interaction site because it could be the site of disease pathogenesis for either ARJP or 
MJD. 
 
4.3 Interactions between the parkin UbLD and UIM region of ataxin-3 
Thorough analysis of eight different sets of NMR titration experiments, using 
multiple ataxin-3 UIM region constructs of various lengths and sequences and the parkin 
UbLD, were carried out to provide the first reports of the site (on parkin) for the 
interaction, strength of the interaction and proposal of a mechanism of binding between 
parkin and ataxin-3. The UIM region of ataxin-3, spanning residues 194-361 (including 
all three UIM sites), were found to bind to the beta-grasp fold on the UbLD of parkin. 
This binding region on the UbLD is called the hydrophobic patch, which includes 
residues Ala46, Ile66, and Val67 as well as a few basic residues, such as Lys48. The beta-
grasp surface on the parkin UbLD is also the binding site for two other UIM-containing 
proteins, S5a and Eps15, though there are variations in the size of the binding surface 
because of the difference in how many UIM sites are utilized in the interaction (8). The 
binding surface area where the UIM region of ataxin-3 binds to the UbLD, in comparison 
to previous studies, can be predicted to bind one to two UIM sites but is not large enough 
to simultaneously interact with all three UIM sites. Interestingly, the NMR titrations 
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involving C-terminal deletions of the ataxin-3 UIM region suggested that when all 
three UIM sites are intact, the binding affinity is the tightest. The evidence for this was 
displayed by determining the KDs by fitting the binding curves to the macroscopic or 
simple 1:1 binding model; the KDs were 230 µM, 430 µM, and >2 mM for ataxin-3 
regions 194-361 (3 UIM sites), 194-261 (2 UIM sites), and 194-244 (1 UIM), 
respectively. This led to the proposal that a multivalent binding mechanism could be 
utilized by all three UIM binding regions of ataxin-3 upon interacting with parkin. 
Multivalent binding involves rapid kinetic substrate binding, of typically a tandem string 
of binding moieties; in this case the ataxin-3 UIM sites were proposed to be 
interchanging amongst one another in an intramolecular fashion at a rapid rate. 
Interestingly, this type of multivalent binding mechanism has been characterized for 
another UIM-containing protein involved in DNA repair, called Rap80, and its 
interaction with poly-ubiquitin chains (9).  
 
4.4 ARJP substitutions on the UbLD and the effect on its interaction with ataxin-
3 
 Three structurally unaffected ARJP substituted UbLD proteins, chosen based on 
residue positions that were within or proximal to the binding surface for ataxin-3, were 
analyzed for their effect on the interaction with ataxin-3 UIM123194-361. Out of 20 
possible ARJP substitutions within the parkin UbLD, the ones that were the focus of this 
study were UbLDV15M, UbLDR33Q, and UbLDK48A (5). All three ARJP substituted proteins 
were able to retain their interaction with the UIM region of ataxin-3, based on an affinity-
tag binding assay. A detailed analysis was carried out for UbLDV15M and UbLDK48A, by 
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1H-15N HSQC titration experiments, for determination of the binding site on the UbLD 
and the binding affinity. Results showed that although the binding site was not identical 
for ataxin-3 binding to UbLDV15M and UbLDK48A, there were many identical residues that 
shifted upon additions of ataxin-3. The binding site on the UbLDK48A and UbLDV15M, 
where the UIM region of ataxin-3 binds, was found to be on the solvent exposed surface 
of the beta-grasp fold, which is where the wildtype binding site is located. The KD values 
for the interaction between the UbLDV15M and UbLDK48A to ataxin-3194-361 were similar to 
that of the wildtype UbLD interaction, all of them within the 650-750 µM range for a 
multivalent binding fit. Therefore, the ARJP-substituted UbLD proteins used in this study 
are all able to interact with ataxin-3 UIM123194-361, and likely uses a similar mechanism 
to recruit ataxin-3 UIM123194-361.  
 
4.5 Conclusions 
The work presented here has contributed to the understanding of how an E3 
ubiquitin ligase, parkin, recognizes a DUB enzyme, ataxin-3. Parkin was previously 
reported to directly interact with ataxin-3 by affinity binding assays but details regarding 
the binding affinity, recognition surface and mechanism of binding were not 
characterized until now (2). This work provides the first detailed understanding of where 
and how the three UIM regions in ataxin-3 make a weak interaction 
(KD,macroscopic=230µM) with the parkin UbLD, and is proposed to use a multivalent 
binding mechanism to do so. Choosing only the structurally unaffected ARJP substituted 
UbLD proteins, based on previous structural characterization, provides the first analysis 
of the disease state UbLD proteins and their effect on the binding affinity and UbLD 
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binding surface upon addition of ataxin-3. These analyses showed that the interaction 
between the UbLDV15M, UbLDR33Q, UbLDK48A and ataxin-3 is retained and that the 
V15M and K48A substitutions do not completely alter the site of interaction on the 
UbLD.  
 The interaction between these two proteins is very interesting because they 
possess opposing functions of either attaching or detaching a Ub moiety from specific 
substrates or one another (2). The interactions between other DUB enzymes and E3 
ligases have been reported, which has triggered interest in studying the biological 
importance and interplay between these protein pairings (2, 6). There is also evidence to 
suggest that there is regulatory interplay for the catalytic activity of parkin and ataxin-3, 
which provides another piece of evidence to explain why their interaction is biologically 
important (2, 4, 7). The USP is a complex system consisting of hundreds of enzymes and 
even more target proteins, which all need to be orchestrated for proper maintenance of 
intracellular protein level homeostasis. Due to the complexity of the USP, there are still 
many protein networks that need to be understood in order to address the 
neurodegenerative USP-linked disease states, such as ARJP and MJD. 
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